U.S. patent application number 12/207722 was filed with the patent office on 2009-01-22 for glucopyranosyl-substituted phenyl derivates, medicaments containing such compounds, their use and process for their manufacture.
This patent application is currently assigned to Boehringer Ingelheim International GmbH. Invention is credited to Edward Leon Barsoumian, Matthias Eckhardt, Peter Eickelmann, Frank Himmelsbach, Leo Thomas.
Application Number | 20090023913 12/207722 |
Document ID | / |
Family ID | 34962236 |
Filed Date | 2009-01-22 |
United States Patent
Application |
20090023913 |
Kind Code |
A1 |
Eckhardt; Matthias ; et
al. |
January 22, 2009 |
GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATES, MEDICAMENTS CONTAINING
SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE
Abstract
Glucopyranosyl-substituted benzene derivatives of general
formula I ##STR00001## where the groups R.sup.1 to R.sup.6 as well
as R.sup.7a, R.sup.7b, R.sup.7c are defined herein and the
tautomers, the stereoisomers thereof, the mixtures thereof and the
salts thereof. The compounds according to the invention are
suitable for the treatment of metabolic disorders.
Inventors: |
Eckhardt; Matthias;
(Biberach, DE) ; Eickelmann; Peter;
(Mittelbiberach, DE) ; Himmelsbach; Frank;
(Mittelbiberach, DE) ; Barsoumian; Edward Leon;
(Saratoga, CA) ; Thomas; Leo; (Biberach,
DE) |
Correspondence
Address: |
MICHAEL P. MORRIS;BOEHRINGER INGELHEIM USA CORPORATION
900 RIDGEBURY ROAD, P. O. BOX 368
RIDGEFIELD
CT
06877-0368
US
|
Assignee: |
Boehringer Ingelheim International
GmbH
Ingelheim
DE
|
Family ID: |
34962236 |
Appl. No.: |
12/207722 |
Filed: |
September 10, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11080150 |
Mar 15, 2005 |
|
|
|
12207722 |
|
|
|
|
60560239 |
Apr 7, 2004 |
|
|
|
Current U.S.
Class: |
536/120 |
Current CPC
Class: |
A61K 9/02 20130101; A61P
3/08 20180101; A61K 9/0019 20130101; A61P 9/12 20180101; A61P 7/10
20180101; A61P 7/00 20180101; A61P 13/12 20180101; A61P 25/00
20180101; C07H 15/20 20130101; C07H 23/00 20130101; A61K 9/2018
20130101; A61P 9/10 20180101; C07H 15/04 20130101; C07H 15/26
20130101; A61P 9/00 20180101; A61P 9/04 20180101; A61P 5/14
20180101; A61P 5/50 20180101; A61P 3/06 20180101; A61P 39/02
20180101; C07D 309/10 20130101; A61P 1/04 20180101; A61P 3/04
20180101; A61P 19/06 20180101; A61P 43/00 20180101; A61K 9/4866
20130101; A61P 3/00 20180101; A61P 1/18 20180101; A61P 3/10
20180101 |
Class at
Publication: |
536/120 |
International
Class: |
C07H 15/04 20060101
C07H015/04 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 16, 2004 |
DE |
DE102004012676.3 |
Aug 18, 2004 |
DE |
DE102004040168.3 |
Dec 16, 2004 |
DE |
DE102004061145.9 |
Feb 9, 2005 |
EP |
EP05002628.5 |
Claims
1.-28. (canceled)
29. Glucopyranosyl-substituted benzene derivatives of general
formula I.2c ##STR00117## wherein R.sup.1 is selected from
hydrogen, fluorine, chlorine, bromine, cyano, methyl, ethyl,
isopropyl, ethynyl, hydroxy, methoxy, ethoxy, cyclobutyloxy,
cyclopentyloxy, cyclohexyloxy, and R.sup.2 is hydrogen, fluorine,
hydroxy, methoxy, ethoxy or methyl, and R.sup.3 is selected from
trimethylsilylethyl, ethynyl, 2-hydroxyprop-2-ylethynyl,
2-methoxyprop-2-ylethynyl, 3-hydroxy-1-propyn-1-yl,
3-methoxy-1-propyn-1-yl, cyclopropyloxy, cyclobutyloxy,
cyclopentyloxy, cyclohexyloxy, tetrahydrofuran-3-yloxy,
tetrahydropyran-4-yloxy, piperidin-4-yloxy,
N-methylpiperidin-4-yloxy and N-acetylpiperidin-4-yloxy, and
R.sup.4, R.sup.5 independently of one another is hydrogen or
fluorine, and R.sup.6 is hydrogen, (C.sub.1-6-alkyl)carbonyl or
(C.sub.1-6-alkyl)oxycarbonyl, and R.sup.7a, R.sup.7b and R.sup.7c
are hydrogen, while, unless otherwise stated, the above-mentioned
alkyl groups may be straight-chain or branched, the stereoisomers
thereof, the mixtures thereof and the salts thereof.
30. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.1 is methyl or chlorine.
31. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.3 is ethynyl.
32. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.3 is trimethylsilylethyl.
33. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.3 is cyclobutyloxy.
34. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.3 is cyclopentyloxy.
35. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.3 is cyclohexyloxy.
36. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.3 is tetrahydrofuran-3-yloxy.
37. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.3 is tetrahydropyran-4-yloxy.
38. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.2 is hydrogen or methyl.
39. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.2 is hydrogen.
40. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.4 and R.sup.5 are hydrogen.
41. Glucopyranosyl-substituted benzene derivatives according to
claim 29, wherein R.sup.6 is hydrogen.
42.
1-Chloro-2-(4-cyclopentyloxybenzyl)-4-(.beta.-D-glucopyranos-1-yl)-be-
nzene.
43.
1-Chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-y-
loxy)-benzyl]-benzene.
44.
1-Chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-y-
loxy)-benzyl]-benzene.
45.
1-Chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-cyclobutyloxy-benzyl)-be-
nzene.
46.
1-Chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-cyclohexyloxy-benzyl)-be-
nzene.
47.
1-Chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(tetrahydropyran-4-yloxy-
)-benzyl]-benzene.
48.
1-Chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(1-acetyl-piperidin-4-yl-
oxy)-benzyl]-benzene.
49.
1-(.beta.-D-Glucopyranos-1-yl)-4-methyl-3-[4-(2-trimethylsilyl-ethyl)-
-benzyl]-benzene.
50.
1-Chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene.
51.
1-Fluoro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene.
52.
1-(.beta.-D-Glucopyranos-1-yl)-3-(4-ethynyl-benzyl)-benzene.
53.
1-Methoxy-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene-
.
Description
RELATED APPLICATIONS
[0001] This application claims benefit of under 35 U.S.C. 119(e)
filed 60/560,239 Apr. 7, 2004, from German application number
DE102004012676.3 filed Mar. 16, 2004, from German application
number DE102004040168.3 filed Aug. 18, 2004, and from German
application number DE102004061145.9 filed Dec. 16, 2004, the
contents of which are incorporated herein.
DESCRIPTION OF THE INVENTION
[0002] The present invention relates to glucopyranosyl-substituted
benzene derivatives of general formula I
##STR00002##
wherein the groups R.sup.1 to R.sup.6 and R.sup.7a, R.sup.7b,
R.sup.7c are as defined hereinafter, including the tautomers, the
stereoisomers, the mixtures thereof and the salts thereof. The
invention further relates to pharmaceutical compositions containing
a compound of formula I according to the invention as well as the
use of a compound according to the invention for preparing a
pharmaceutical composition for the treatment of metabolic
disorders. In addition, the invention relates to processes for
preparing a pharmaceutical composition as well as a compound
according to the invention.
[0003] In the literature, compounds which have an inhibitory effect
on the sodium-dependent glucose cotransporter SGLT2 are proposed
for the treatment of diseases, particularly diabetes.
[0004] Glucopyranosyloxy-substituted aromatic groups and the
preparation thereof and their possible activity as SGLT2 inhibitors
are known from published International applications WO 98/31697, WO
01/27128, WO 02/083066, WO 03/099836, WO 2004/063209, WO
2004/080990, WO 2004/013118, WO 2004/052902, WO 2004/052903 and US
application US 2003/0114390.
Aim of the Invention
[0005] The aim of the present invention is to find new
pyranosyloxy-substituted benzene derivatives, particularly those
which are active with regard to the sodium-dependent glucose
cotransporter SGLT, particularly SGLT2. A further aim of the
present invention is to discover pyranosyloxy-substituted benzene
derivatives which have an enhanced inhibitory effect on the
sodium-dependent glucose cotransporter SGLT2 in vitro and/or in
vivo compared with known, structurally similar compounds and/or
have better pharmacological or pharmacokinetic properties.
[0006] A further aim of the present invention is to provide new
pharmaceutical compositions which are suitable for the prevention
and/or treatment of metabolic disorders, particularly diabetes.
[0007] The invention also sets out to provide a process for
preparing the compounds according to the invention.
[0008] Other aims of the present invention will become apparent to
the skilled man directly from the foregoing and following
remarks.
OBJECT OF THE INVENTION
[0009] In a first aspect the present invention relates to
glucopyranosyloxy-substituted benzene derivatives of general
formula I
##STR00003##
wherein [0010] R.sup.1 is selected from the definitions of the
group A and if R.sup.3 is selected from the definitions of the
group B, R.sup.1 may additionally also be selected from the
meanings hydrogen, fluorine, chlorine, bromine, iodine,
C.sub.1-4-alkyl, C.sub.2-4-alkenyl-C.sub.1-4-alkyl,
C.sub.2-4-alkynyl-C.sub.1-4-alkyl,
C.sub.2-4-alkenyl-C.sub.1-4-alkoxy,
C.sub.2-4-alkynyl-C.sub.1-4-alkoxy,
C.sub.3-7-cycloalkyl-C.sub.1-4-alkyl,
C.sub.5-7-cycloalkenyl-C.sub.1-4-alkyl, a methyl group substituted
by 1 to 3 fluorine atoms, an ethyl group substituted by 1 to 5
fluorine atoms, C.sub.1-4-alkoxy, a methoxy group substituted by 1
to 3 fluorine atoms, an ethoxy group substituted by 1 to 5 fluorine
atoms, a C.sub.1-4-alkyl group substituted by a hydroxy or
C.sub.1-3-alkoxy group, a C.sub.2-4-alkoxy group substituted by a
hydroxy or C.sub.1-3-alkoxy group,
C.sub.3-6-cycloalkyl-C.sub.1-3-alkoxy or hydroxy, [0011] while in
the above-mentioned cycloalkyl and cycloalkenyl rings one or two
methylene groups may be replaced independently of one another by O
or CO, and [0012] R.sup.2 denotes hydrogen, fluorine, chlorine,
bromine, hydroxy, C.sub.1-4-alkyl, C.sub.1-4-alkoxy, cyano or
nitro, while the alkyl or alkoxy group may be mono- or
polysubstituted by fluorine, and [0013] R.sup.3 is selected from
the definitions of the group B and [0014] if R.sup.1 is selected
from the definitions of the group A, R.sup.3 may additionally also
be selected from the meanings hydrogen, fluorine, chlorine,
bromine, iodine, C.sub.1-6-alkyl,
C.sub.2-4-alkenyl-C.sub.1-4-alkyl,
C.sub.2-4-alkynyl-C.sub.1-4-alkyl,
C.sub.2-4-alkenyl-C.sub.1-4-alkoxy,
C.sub.2-4-alkynyl-C.sub.1-4-alkoxy, C.sub.3-7-cycloalkyl,
C.sub.5-7-cycloalkenyl, C.sub.3-7-cycloalkyl-C.sub.1-4-alkyl,
C.sub.5-7-cycloalkenyl-C.sub.1-4-alkyl,
C.sub.3-6-cycloalkylidenmethyl, hydroxy, C.sub.1-6-alkoxy,
C.sub.3-6-cycloalkyl-C.sub.1-3-alkoxy, aryl, aryl-C.sub.1-3-alkyl,
heteroaryl, heteroaryl-C.sub.1-3-alkyl, aryloxy,
aryl-C.sub.1-3-alkyl-oxy, a methyl or methoxy group substituted by
1 to 3 fluorine atoms, a C.sub.2-4-alkyl or C.sub.2-4-alkoxy group
substituted by 1 to 5 fluorine atoms, a C.sub.1-4-alkyl group
substituted by a cyano group, a C.sub.1-4-alkyl group substituted
by a hydroxy or C.sub.1-3-alkyloxy group, cyano, carboxy,
C.sub.1-3-alkoxycarbonyl, aminocarbonyl,
(C.sub.1-3-alkylamino)carbonyl, di-(C.sub.1-3-alkyl)aminocarbonyl,
pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl,
morpholin-4-ylcarbonyl, piperazin-1-yl-carbonyl,
4-(C.sub.1-3-alkyl)-piperazin-1-ylcarbonyl,
(C.sub.1-4-alkyl)carbonylamino, C.sub.1-4-alkyl-sulphonylamino,
C.sub.1-4-alkylsulphanyl, C.sub.1-4-alkylsulphinyl,
C.sub.1-4-alkylsulphonyl, arylsulphonylamino,
aryl-C.sub.1-3-alkylsulphonylamino or arylsulphonyl, [0015]
R.sup.4, R.sup.5 independently of one another denote hydrogen,
fluorine, chlorine, bromine, iodine, cyano, nitro, C.sub.1-3-alkyl,
C.sub.1-3-alkoxy, methyl or methoxy substituted by 1 to 3 fluorine
atoms, [0016] A denotes C.sub.2-6-alkyn-1-yl, C.sub.2-6-alken-1-yl,
C.sub.3-7-cycloalkyl, C.sub.5-7-cycloalkenyl, aryl, heteroaryl,
C.sub.1-4-alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl,
aminocarbonyl, C.sub.1-4-alkylaminocarbonyl,
di-(C.sub.1-3-alkyl)aminocarbonyl, pyrrolidin-1-ylcarbonyl,
piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl,
piperazin-1-ylcarbonyl, 4-(C.sub.1-4-alkyl)piperazin-1-ylcarbonyl,
arylamino-carbonyl, heteroarylaminocarbonyl,
C.sub.1-4-alkoxycarbonyl, aryl-C.sub.1-13-alkoxycarbonyl,
heteroaryl-C.sub.1-3-alkoxycarbonyl, amino, C.sub.1-4-alkylamino,
di-(C.sub.1-3-alkyl)amino, pyrrolidin-1-yl, pyrrolidin-2-on-1-yl,
piperidin-1-yl, piperidin-2-on-1-yl, morpholin-4-yl,
morpholin-3-on-4-yl, piperazin-1-yl,
4-(C.sub.1-3-alkyl)piperazin-1-yl, C.sub.1-4-alkylcarbonylamino,
arylcarbonylamino, heteroarylcarbonylamino,
C.sub.3-7-cycloalkyloxy, C.sub.5-7-cycloalkenyloxy, aryloxy,
heteroaryloxy, C.sub.1-4-alkylsulphinyl, C.sub.1-4-alkylsulphonyl,
C.sub.3-7-cycloalkylsulphanyl, C.sub.3-7-cycloalkylsulphinyl,
C.sub.3-7-cycloalkylsulphonyl, C.sub.5-7-cycloalkenylsulphanyl,
C.sub.5-7-cycloalkenylsulphinyl, C.sub.5-7-cycloalkenylsulphonyl,
arylsulphanyl, arylsulphinyl, arylsulphonyl, heteroarylsulphanyl,
heteroarylsulphinyl, heteroarylsulphonyl, cyano or nitro, [0017]
while the above-mentioned alkynyl and alkenyl groups may be mono-
or polysubstituted by fluorine or chlorine, and [0018] the
above-mentioned alkynyl and alkenyl groups may be mono- or
disubstituted by identical or different groups L1, and [0019] the
above-mentioned cycloalkyl and cycloalkenylrings independently of
one another may be mono- or disubstituted by substituents selected
from fluorine and C.sub.1-3-alkyl, and [0020] in the
above-mentioned cycloalkyl and cycloalkenyl rings one or two
methylene groups may be replaced independently of one another by O,
S, CO, SO, SO.sub.2 or NR.sup.N, [0021] B denotes
tri-(C.sub.1-4-alkyl)silyl-C.sub.1-6-alkyl, C.sub.2-6-alkyn-1-yl,
C.sub.2-6-alken-1-yl, amino, C.sub.1-3-alkylamino,
di-(C.sub.1-3-alkyl)amino, pyrrolidin-1-yl, pyrrolidin-2-on-1-yl,
piperidin-1-yl, piperidin-2-on-1-yl, morpholin-4-yl,
morpholin-3-on-4-yl, piperazin-1-yl,
4-(C.sub.1-3-alkyl)piperazin-1-yl, arylcarbonylamino,
heteroarylcarbonylamino, nitro, C.sub.3-10-cycloalkyloxy,
C.sub.5-10-cycloalkenyloxy, C.sub.3-10-cycloalkylsulphanyl,
C.sub.3-10-cycloalkylsulphinyl, C.sub.3-10-cycloalkylsulphonyl,
C.sub.5-10-cycloalkenylsulphanyl, C.sub.5-10-cycloalkenylsulphinyl,
C.sub.5-10-cycloalkenyl-sulphonyl, arylsulphanyl, arylsulphinyl,
heteroarylsulphanyl or heteroarylsulphinyl, [0022] while the
above-mentioned alkynyl and alkenyl groups may be mono- or
polysubstituted by fluorine or chlorine, and [0023] the
above-mentioned alkynyl and alkenyl groups may be mono- or
disubstituted by identical or different groups L1; [0024] while the
above-mentioned cycloalkyl and cycloalkenyl rings may be mono- or
disubstituted independently of one another by substituents selected
from fluorine and C.sub.1-3-alkyl, and [0025] in the
above-mentioned cycloalkyl and cycloalkenyl rings one or two
methylene groups may be replaced independently of one another by O,
S, CO, SO, SO.sub.2 or NR.sup.N, [0026] R.sup.N denotes H,
C.sub.1-4-alkyl, C.sub.1-4-alkylcarbonyl or
C.sub.1-4-alkylsulphonyl, [0027] L1 independently of one another
are selected from among hydroxy, cyano, nitro,
C.sub.3-7-cycloalkyl, aryl, heteroaryl, C.sub.1-4-alkylcarbonyl,
arylcarbonyl, heteroarylcarbonyl, aminocarbonyl,
C.sub.1-4-alkylaminocarbonyl, di-(C.sub.1-3-alkyl)-aminocarbonyl,
pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl,
morpholin-4-ylcarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,
C.sub.1-4-alkoxycarbonyl, aryl-C.sub.1-3-alkoxycarbonyl,
heteroaryl-C.sub.1-3-alkoxycarbonyl, C.sub.1-4-alkyloxy, aryloxy,
heteroaryloxy, C.sub.1-4-alkylsulphanyl, arylsulphanyl,
heteroarylsulphanyl, C.sub.1-4-alkylsulphinyl, arylsulphinyl,
heteroarylsulphinyl, C.sub.1-4-alkylsulphonyl, arylsulphonyl and
heteroarylsulphonyl; and [0028] L2 independently of one another are
selected from among fluorine, chlorine, bromine, iodine,
C.sub.1-3-alkyl, difluoromethyl, trifluoromethyl, C.sub.1-3-alkoxy,
difluoromethoxy, trifluoromethoxy and cyano; and [0029] R.sup.6,
R.sup.7a, [0030] R.sup.7b, R.sup.7c independently of one another
have a meaning selected from among hydrogen,
(C.sub.1-18-alkyl)carbonyl, (C.sub.1-18-alkyl)oxycarbonyl,
arylcarbonyl and aryl-(C.sub.1-3-alkyl)-carbonyl, while by the aryl
groups mentioned in the definition of the above groups are meant
phenyl or naphthyl groups which may be mono- or disubstituted
independently of one another by identical or different groups L2;
and by the heteroaryl groups mentioned in the definition of the
above groups are meant a pyrrolyl, furanyl, thienyl, pyridyl,
indolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl
or tetrazolyl group, or is meant a pyrrolyl, furanyl, thienyl or
pyridyl group, wherein one or two methyne groups are replaced by
nitrogen atoms, or is meant an indolyl, benzofuranyl,
benzothiophenyl, quinolinyl or isoquinolinyl group, wherein one to
three methyne groups are replaced by nitrogen atoms, while the
above-mentioned heteroaryl groups independently of one another may
be mono- or disubstituted by identical or different groups L2;
while, unless otherwise stated, the above-mentioned alkyl groups
may be straight-chain or branched, the tautomers, the stereoisomers
thereof, the mixtures thereof and the salts thereof.
[0031] The compounds of general formula I according to the
invention and the physiologically acceptable salts thereof have
valuable pharmacological properties, particularly an inhibitory
effect on the sodium-dependent glucose cotransporter SGLT,
particularly SGLT2. Moreover compounds according to the invention
may have an inhibitory effect on the sodium-dependent glucose
cotransporter SGLT1. Compared with a possible inhibitory effect on
SGLT1 the compounds according to the invention preferably inhibit
SGLT2 selectively.
[0032] The present invention also relates to the physiologically
acceptable salts of the compounds according to the invention with
inorganic or organic acids.
[0033] This invention also relates to pharmaceutical compositions,
containing at least one compound according to the invention or a
physiologically acceptable salt according to the invention,
optionally together with one or more inert carriers and/or
diluents.
[0034] This invention also relates to the use of at least one
compound according to the invention or one of the physiologically
acceptable salts thereof for preparing a pharmaceutical composition
which is suitable for the treatment or prevention or diseases or
conditions which can be influenced by inhibiting the
sodium-dependent glucose cotransporter SGLT, particularly
SGLT2.
[0035] This invention also relates to the use of at least one
compound according to the invention or one of the physiologically
acceptable salts thereof for preparing a pharmaceutical composition
which is suitable for the treatment of metabolic disorders.
[0036] This invention also relates to the use of at least one
compound according to the invention or one of the physiologically
acceptable salts thereof for preparing a pharmaceutical composition
for inhibiting the sodium-dependent glucose cotransporter SGLT,
particularly SGLT2.
[0037] The invention further relates to a process for preparing a
pharmaceutical composition according to the invention,
characterised in that a compound according to the invention or one
of the physiologically acceptable salts thereof is incorporated in
one or more inert carriers and/or diluents by a non-chemical
method.
[0038] The present invention also relates to a process for
preparing the compounds of general formula I according to the
invention, characterised in that
a) in order to prepare compounds of general formula I which are
defined as hereinbefore and hereinafter, a compound of general
formula II
##STR00004##
wherein [0039] R' denotes H, C.sub.1-4-alkyl,
(C.sub.1-18-alkyl)carbonyl, (C.sub.1-18-alkyl)oxycarbonyl,
arylcarbonyl and aryl-(C.sub.1-3-alkyl)-carbonyl, wherein the alkyl
or aryl groups may be mono- or polysubstituted by halogen; [0040]
R.sup.8a, R.sup.8b, [0041] R.sup.8c, R.sup.8d independently of one
another have one of the meanings given hereinbefore and hereinafter
for the groups R.sup.6, R.sup.7a, R.sup.7b, R.sup.7c, denote a
benzyl group or a R.sup.aR.sup.bR.sup.cSi group or a ketal or
acetal group, particularly an alkylidene or arylalkylidene ketal or
acetal group, while in each case two adjacent groups R.sup.8a,
R.sup.8b, R.sup.8c, R.sup.8d may form a cyclic ketal or acetal
group or a
1,2-di(C.sub.1-3-alkoxy)-1,2-di(C.sub.1-3-alkyl)-ethylene bridge,
while the above-mentioned ethylene bridge forms, together with two
oxygen atoms and the two associated carbon atoms of the pyranose
ring, a substituted dioxane ring, particularly a
2,3-dimethyl-2,3-di(C.sub.1-3-alkoxy)-1,4-dioxane ring, and alkyl,
aryl and/or benzyl groups may be mono- or polysubstituted by
halogen or C.sub.1-3-alkoxy and benzyl groups may also be
substituted by a di-(C.sub.1-3-alkyl)amino group; and [0042]
R.sup.a, R.sup.b, R.sup.c independently of one another denote
C.sub.1-4-alkyl, aryl or aryl-C.sub.1-3-alkyl, wherein the aryl or
alkyl groups may be mono- or polysubstituted by halogen; while by
the aryl groups mentioned in the definition of the above groups are
meant phenyl or naphthyl groups, preferably phenyl groups; and
wherein the groups R.sup.1 to R.sup.5 and R.sup.6, R.sup.7a,
R.sup.7b, R.sup.7c are defined as hereinbefore and hereinafter; is
reacted with a reducing agent in the presence of a Lewis or
Bronsted acid, while the any protective groups present are cleaved
simultaneously or subsequently; or b) in order to prepare compounds
of general formula I wherein R.sup.6, R.sup.7a, R.sup.7b and
R.sup.7c denote hydrogen, a compound of general formula III
##STR00005##
[0042] wherein R.sup.8a, R.sup.8b, R.sup.8c, R.sup.8d and R.sup.1
to R.sup.5 are defined as hereinbefore and hereinafter, but at
least one of the groups R.sup.8a, R.sup.8b, R.sup.8c, R.sup.8d does
not denote hydrogen, is hydrolysed, and if desired a compound of
general formula I thus obtained wherein R.sup.6 denotes a hydrogen
atom, is converted by acylation into a corresponding acyl compound
of general formula I, and/or if necessary any protective group used
in the reactions described above is cleaved and/or if desired a
compound of general formula I thus obtained is resolved into its
stereoisomers and/or if desired a compound of general formula I
thus obtained is converted into the salts thereof, particularly for
pharmaceutical use into the physiologically acceptable salts
thereof.
[0043] This invention further relates to a process for preparing
compounds of general formula II
##STR00006##
wherein [0044] R' denotes H, C.sub.1-4-alkyl,
(C.sub.1-18-alkyl)carbonyl, (C.sub.1-18-alkyl)oxycarbonyl,
arylcarbonyl and aryl-(C.sub.1-3-alkyl)-carbonyl, wherein the alkyl
or aryl groups may be mono- or polysubstituted by halogen; [0045]
R.sup.8a, R.sup.8b, [0046] R.sup.8c, R.sup.8d independently of one
another has one of the meanings given for the groups R.sup.6,
R.sup.7a, R.sup.7b, R.sup.7c, denote a benzyl group or a
R.sup.aR.sup.bR.sup.cSi group or a ketal or acetal group, while in
each case two adjacent groups R.sup.8a, R.sup.8b, R.sup.8c,
R.sup.8d may form a cyclic ketal or acetal group or may form, with
two oxygen atoms of the pyranose ring, a substituted 2,3-oxydioxane
ring, particularly a
2,3-dimethyl-2,3-di(C.sub.1-3-alkoxy)-1,4-dioxane ring, and alkyl,
aryl and/or benzyl groups may be mono- or polysubstituted by
halogen or C.sub.1-3-alkoxy and benzyl groups may also be
substituted by a di-(C.sub.1-3-alkyl)amino group; and [0047]
R.sup.a, R.sup.b, R.sup.c independently of one another denote
C.sub.1-4-alkyl, aryl or aryl-C.sub.1-3-alkyl, while the alkyl or
aryl groups may be mono- or polysubstituted by halogen; while by
the aryl groups mentioned in the definition of the above groups are
meant phenyl or naphthyl groups, preferably phenyl groups; and
R.sup.1 to R.sup.5, R.sup.6, R.sup.7a, R.sup.7b, R.sup.7c are
defined as hereinbefore and hereinafter, wherein an organometallic
compound (V) which may be obtained by halogen-metal exchange or by
inserting a metal in the carbon-halogen bond of a
halogen-benzylbenzene compound of general formula IV
##STR00007##
[0047] wherein Hal denotes Cl, Br and I and R.sup.1 to R.sup.5 are
defined as hereinbefore and hereinafter, and optionally subsequent
transmetallation, is added to a gluconolactone of general formula
VI
##STR00008##
wherein R.sup.8a, R.sup.8b, R.sup.8c, R.sup.8d are defined as
hereinbefore and hereinafter, and then the resulting adduct, is
reacted, preferably in situ, with water or an alcohol R'--OH, while
R' denotes optionally substituted C.sub.1-4-alkyl, in the presence
of an acid, such as for example methanesulphonic acid, sulphuric
acid, hydrochloric acid, acetic acid or ammonium chloride, and
optionally the product obtained in the reaction with water wherein
R' denotes H is converted, in a subsequent reaction, with an
acylating agent, such as for example the corresponding acid
chloride or anhydride, into the product of formula II wherein R'
denotes (C.sub.1-18-alkyl)carbonyl, (C.sub.1-18-alkyl)oxycarbonyl,
arylcarbonyl or aryl-(C.sub.1-3-alkyl)-carbonyl, which may be
substituted as specified.
[0048] The intermediate products listed, particularly those of
formula IV, formula II and formula III, are also a subject of this
invention.
DETAILED DESCRIPTION OF THE INVENTION
[0049] Unless otherwise stated, the groups, residues and
substituents, particularly R.sup.1 to R.sup.5, A, B, L1, L2,
R.sup.N, R.sup.6, R.sup.7a, R.sup.7b, R.sup.7c, R.sup.8a, R.sup.8b,
R.sup.8c, R.sup.8d, are defined as above and hereinafter.
[0050] If residues, substituents or groups occur several times in a
compound, they may have the same or different meanings.
[0051] According to the invention preferred
glucopyranosyl-substituted benzene derivatives are those of general
formula I
##STR00009##
wherein [0052] R.sup.1 is selected from the definitions of the
group A and [0053] if R.sup.3 is selected from the definitions of
the group B, R.sup.1 may additionally also be selected from the
meanings hydrogen, fluorine, chlorine, bromine, iodine,
C.sub.1-4-alkyl, C.sub.2-4-alkenyl-C.sub.1-4-alkyl,
C.sub.2-4-alkynyl-C.sub.1-4-alkyl,
C.sub.3-7-cycloalkyl-C.sub.1-4-alkyl,
C.sub.5-7-cycloalkenyl-C.sub.1-4-alkyl, a methyl group substituted
by 1 to 3 fluorine atoms, an ethyl group substituted by 1 to 5
fluorine atoms, C.sub.1-4-alkoxy, a methoxy group substituted by 1
to 3 fluorine atoms, an ethoxy group substituted by 1 to 5 fluorine
atoms, a C.sub.1-4-alkyl group substituted by a hydroxy or
C.sub.1-3-alkoxy group, a C.sub.2-4-alkoxy group substituted by a
hydroxy or C.sub.1-3-alkoxy group,
C.sub.3-6-cycloalkyl-C.sub.1-3-alkoxy or hydroxy, [0054] while in
the above-mentioned cycloalkyl and cycloalkenyl rings one or two
methylene groups may be replaced independently of one another by O
or CO, and [0055] R.sup.2 denotes hydrogen, fluorine, chlorine,
bromine, hydroxy, C.sub.1-4-alkyl, C.sub.1-4-alkoxy, cyano or
nitro, while the alkyl or alkoxy group may be mono- or
polysubstituted by fluorine, and [0056] R.sup.3 is selected from
the definitions of the group B and [0057] if R.sup.1 is selected
from the definitions of the group A, R.sup.3 may additionally also
be selected from the meanings hydrogen, fluorine, chlorine,
bromine, iodine, C.sub.1-6-alkyl,
C.sub.2-4-alkenyl-C.sub.1-4-alkyl,
C.sub.2-4-alkynyl-C.sub.1-4-alkyl, C.sub.3-7-cycloalkyl,
C.sub.5-7-cycloalkenyl, C.sub.3-7-cycloalkyl-C.sub.1-4-alkyl,
C.sub.5-7-cycloalkenyl-C.sub.1-4-alkyl,
C.sub.3-6-cycloalkylidenemethyl, hydroxy, C.sub.1-6-alkoxy,
C.sub.3-6-cycloalkyl-C.sub.1-3-alkoxy, aryl, aryl-C.sub.1-3-alkyl,
heteroaryl, heteroaryl-C.sub.1-3-alkyl, aryloxy,
aryl-C.sub.1-3-alkyl-oxy, a methyl or methoxy group substituted by
1 to 3 fluorine atoms, a C.sub.2-4-alkyl or C.sub.2-4-alkoxy group
substituted by 1 to 5 fluorine atoms, a C.sub.1-4-alkyl group
substituted by a cyano group, a C.sub.1-4-alkyl group substituted
by a hydroxy or C.sub.1-3-alkyloxy group, cyano, carboxy,
C.sub.1-3-alkoxycarbonyl, aminocarbonyl,
(C.sub.1-3-alkylamino)carbonyl, di-(C.sub.1-3-alkyl)aminocarbonyl,
pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl,
morpholin-4-ylcarbonyl, piperazin-1-yl-carbonyl,
4-(C.sub.1-3-alkyl)-piperazin-1-ylcarbonyl,
(C.sub.1-4-alkyl)carbonylamino, C.sub.1-4-alkyl-sulphonylamino,
C.sub.1-4-alkylsulphanyl, C.sub.1-4-alkylsulphinyl,
C.sub.1-4-alkylsulphonyl, arylsulphonylamino,
aryl-C.sub.1-3-alkylsulphonylamino or arylsulphonyl, [0058]
R.sup.4, R.sup.5 independently of one another denote hydrogen,
fluorine, chlorine, bromine, iodine, cyano, nitro, C.sub.1-3-alkyl,
C.sub.1-3-alkoxy, methyl or methoxy substituted by 1 to 3 fluorine
atoms, [0059] A denotes C.sub.2-6-alkyn-1-yl, C.sub.2-6-alken-1-yl,
C.sub.3-7-cycloalkyl, C.sub.5-7-cycloalkenyl, aryl, heteroaryl,
C.sub.1-4-alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl,
aminocarbonyl, C.sub.1-4-alkylaminocarbonyl,
di-(C.sub.1-3-alkyl)aminocarbonyl, pyrrolidin-1-ylcarbonyl,
piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl,
piperazin-1-ylcarbonyl, 4-(C.sub.1-4-alkyl)piperazin-1-ylcarbonyl,
arylaminocarbonyl, heteroarylaminocarbonyl,
C.sub.1-4-alkoxycarbonyl, aryl-C.sub.1-3-alkoxycarbonyl,
heteroaryl-C.sub.1-3-alkoxycarbonyl, amino, C.sub.1-4-alkylamino,
di-(C.sub.1-3-alkyl)amino, pyrrolidin-1-yl, pyrrolidin-2-on-1-yl,
piperidin-1-yl, piperidin-2-on-1-yl, morpholin-4-yl,
morpholin-3-on-4-yl, piperazin-1-yl,
4-(C.sub.1-3-alkyl)-piperazin-1-yl, C.sub.1-4-alkylcarbonylamino,
arylcarbonylamino, heteroarylcarbonylamino,
C.sub.3-7-cycloalkyloxy, C.sub.5-7-cycloalkenyloxy, aryloxy,
heteroaryloxy, C.sub.1-4-alkylsulphinyl, C.sub.1-4-alkylsulphonyl,
C.sub.3-7-cycloalkylsulphanyl, C.sub.3-7-cycloalkylsulphinyl,
C.sub.3-7-cycloalkylsulphonyl, C.sub.5-7-cycloalkenylsulphanyl,
C.sub.5-7-cycloalkenylsulphinyl, C.sub.5-7-cycloalkenylsulphonyl,
arylsulphanyl, arylsulphinyl, arylsulphonyl, heteroarylsulphanyl,
heteroarylsulphinyl, heteroarylsulphonyl, cyano or nitro, [0060]
while the above-mentioned alkynyl- and alkenyl groups may be mono-
or polysubstituted by fluorine or chlorine, and [0061] while the
above-mentioned alkynyl and alkenyl groups may be mono- or
disubstituted by identical or different groups L1, and [0062] the
above-mentioned cycloalkyl and cycloalkenyl rings may be mono- or
disubstituted independently of one another by substituents selected
from fluorine and C.sub.1-3-alkyl, and [0063] in the
above-mentioned cycloalkyl and cycloalkenyl rings one or two
methylene groups may be replaced independently of one another by O,
S, CO, SO, SO.sub.2 or NR.sup.N, [0064] B denotes
tri-(C.sub.1-4-alkyl)silyl-C.sub.1-6-alkyl, C.sub.2-6-alkyn-1-yl,
C.sub.2-6-alken-1-yl, amino, C.sub.1-3-alkylamino,
di-(C.sub.1-3-alkyl)amino, pyrrolidin-1-yl, pyrrolidin-2-on-1-yl,
piperidin-1-yl, piperidin-2-on-1-yl, morpholin-4-yl,
morpholin-3-on-4-yl, piperazin-1-yl,
4-(C.sub.1-3-alkyl)piperazin-1-yl, arylcarbonylamino,
heteroarylcarbonylamino, nitro, C.sub.3-7-cycloalkyloxy,
C.sub.5-7cycloalkenyloxy, C.sub.3-7-cycloalkylsulphanyl,
C.sub.3-7-cycloalkylsulphinyl, C.sub.3-7-cycloalkylsulphonyl,
C.sub.5-7-cycloalkenylsulphanyl, C.sub.5-7-cycloalkenylsulphinyl,
C.sub.5-7-cycloalkenylsulphonyl, arylsulphanyl, arylsulphinyl,
heteroarylsulphanyl or heteroarylsulphinyl, [0065] while the
above-mentioned alkynyl and alkenyl groups may be mono- or
polysubstituted by fluorine or chlorine, and [0066] the
above-mentioned alkynyl and alkenyl groups may be mono- or
disubstituted by identical or different groups L1; [0067] the
above-mentioned cycloalkyl and cycloalkenyl rings may be mono- or
disubstituted independently of one another by substituents selected
from fluorine and C.sub.1-3-alkyl, and [0068] in the
above-mentioned cycloalkyl and cycloalkenyl rings one or two
methylene groups may be replaced independently of one another by O,
S, CO, SO, SO.sub.2 or NR.sup.N, [0069] R.sup.N denotes H or
C.sub.1-4-alkyl, [0070] L1 independently of one another are
selected from among cyano, nitro, aryl, heteroaryl,
C.sub.1-4-alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl,
aminocarbonyl, C.sub.1-4-alkylaminocarbonyl,
di-(C.sub.1-3-alkyl)aminocarbonyl, pyrrolidin-1-ylcarbonyl,
piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, arylaminocarbonyl,
heteroarylaminocarbonyl, C.sub.1-4-alkoxycarbonyl,
aryl-C.sub.1-3-alkoxycarbonyl, heteroaryl-C.sub.1-3-alkoxycarbonyl,
C.sub.1-4-alkyloxy, aryloxy, heteroaryloxy,
C.sub.1-4-alkylsulphanyl, arylsulphanyl, heteroarylsulphanyl,
C.sub.1-4-alkylsulphinyl, arylsulphinyl, heteroarylsulphinyl,
C.sub.1-4-alkylsulphonyl, arylsulphonyl and heteroarylsulphonyl;
and [0071] L2 independently of one another are selected from among
fluorine, chlorine, bromine, iodine, C.sub.1-3-alkyl,
difluoromethyl, trifluoromethyl, C.sub.1-3-alkoxy, difluoromethoxy,
trifluoromethoxy and cyano; and [0072] R.sup.6, R.sup.7a, [0073]
R.sup.7b, R.sup.7c independently of one another have a meaning
selected from among hydrogen, (C.sub.1-18-alkyl)carbonyl,
(C.sub.1-18-alkyl)oxycarbonyl, arylcarbonyl and
aryl-(C.sub.1-3-alkyl)-carbonyl, while by the aryl groups mentioned
in the definition of the above groups are meant phenyl or naphthyl
groups, which may be mono- or disubstituted independently of one
another by identical or different groups L2; and by the heteroaryl
groups mentioned in the definition of the above groups are meant a
pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl,
benzothiophenyl, quinolinyl or isoquinolinyl group, or is meant a
pyrrolyl, furanyl, thienyl or pyridyl group, wherein one or two
methyne groups are replaced by nitrogen atoms, or is meant an
indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl
group, wherein one to three methyne groups are replaced by nitrogen
atoms, while the above-mentioned heteroaryl groups may be mono- or
disubstituted independently of one another by identical or
different groups L2; while, unless otherwise stated, the
above-mentioned alkyl groups may be straight-chain or branched, the
tautomers, the stereoisomers thereof, the mixtures thereof and the
salts thereof.
[0074] Some preferred meanings of individual groups and
substituents of the compounds according to the invention will be
given hereinafter.
[0075] The group R.sup.3 is preferably in the meta or para position
to the --CH.sub.2 bridge, so that compounds according to the
following formulae I.1 and I.2, particularly formula I.2, are
preferred:
##STR00010##
[0076] The term aryl appearing in the groups L1, R.sup.1, R.sup.3,
A and B preferably denotes phenyl.
[0077] The term heteroaryl occurring in the groups L1, R.sup.1,
R.sup.3, A and B preferably denotes pyridinyl, pyrimidinyl,
pyridazinyl, pyrazinyl, triazinyl, imidazolyl, pyrazolyl,
triazolyl, tetrazolyl, oxazolyl, oxadiazolyl, thiazolyl or
thiadiazolyl.
[0078] The group A preferably denotes C.sub.2-6-alkyn-1-yl,
C.sub.2-6-alken-1-yl, C.sub.3-7-cycloalkyl, C.sub.5-7-cycloalkenyl,
C.sub.1-4-alkylcarbonyl, aminocarbonyl,
C.sub.1-4-alkylaminocarbonyl, di-(C.sub.1-3-alkyl)aminocarbonyl,
pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl,
morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl,
4-(C.sub.1-4-alkyl)piperazin-1-ylcarbonyl,
C.sub.1-4-alkoxycarbonyl, amino, C.sub.1-4-alkylamino,
di-(C.sub.1-3-alkyl)amino, pyrrolidin-1-yl, pyrrolidin-2-on-1-yl,
piperidin-1-yl, piperidin-2-on-1-yl, morpholin-4-yl,
morpholin-3-on-4-yl, piperazin-1-yl,
4-(C.sub.1-3-alkyl)piperazin-1-yl, C.sub.1-4-alkylcarbonylamino,
C.sub.3-7-cycloalkyloxy, C.sub.5-7-cycloalkenyloxy,
C.sub.1-4-alkylsulphinyl, C.sub.1-4-alkylsulphonyl,
C.sub.3-7-cycloalkylsulphanyl, C.sub.3-7-cycloalkylsulphinyl,
C.sub.3-7-cycloalkylsulphonyl, C.sub.5-7-cyclo-alkenylsulphanyl,
C.sub.5-7-cycloalkenylsulphinyl, C.sub.5-7-cycloalkenylsulphonyl,
cyano and nitro,
while the above-mentioned alkynyl and alkenyl groups may be mono-
or polysubstituted by fluorine or chlorine, preferably fluorine,
and the above-mentioned alkynyl and alkenyl groups may be mono- or
disubstituted by identical or different groups L1, and the
above-mentioned cycloalkyl and cycloalkenyl rings may be mono- or
disubstituted independently of one another by substituents selected
from fluorine and C.sub.1-3-alkyl, and in the above-mentioned
cycloalkyl and cycloalkenyl rings one or two methylene groups may
be replaced independently of one another by O, S, CO, SO, SO.sub.2
or NR.sup.N, preferably O or CO, most particularly preferably by
O.
[0079] Particularly preferably, the group A denotes
C.sub.2-6-alkyn-1-yl, C.sub.2-6-alken-1-yl, C.sub.3-7-cycloalkyl,
C.sub.5-7-cycloalkenyl, C.sub.3-7-cycloalkyloxy,
C.sub.5-7-cycloalkenyloxy, C.sub.1-4-alkylsulphinyl,
C.sub.1-4-alkylsulphonyl, C.sub.3-7-cycloalkylsulphanyl,
C.sub.3-7-cycloalkylsulphinyl, C.sub.3-7-cycloalkylsulphonyl,
C.sub.5-7-cycloalkenylsulphanyl, C.sub.5-7-cycloalkenylsulphinyl,
C.sub.5-7-cycloalkenylsulphonyl, cyano and nitro,
while the above-mentioned alkynyl and alkenyl groups may be mono-
or polysubstituted by fluorine or chlorine, preferably fluorine,
and the above-mentioned alkynyl and alkenyl groups may be mono- or
disubstituted by identical or different groups L1, and the
above-mentioned cycloalkyl and cycloalkenyl rings may be mono- or
disubstituted independently of one another by substituents selected
from fluorine and C.sub.1-3-alkyl, and in the above-mentioned
C.sub.5-6-cycloalkyl rings a methylene group may be replaced by
O.
[0080] Most particularly preferably, the group A denotes
C.sub.2-6-alkyn-1-yl, C.sub.2-6-alken-1-yl, C.sub.3-7-cycloalkyl,
C.sub.3-7-cycloalkyloxy, cyano, while in C.sub.5-6-cycloalkyl
groups a methylene unit may be replaced by O.
[0081] Examples of the most particularly preferred definitions of
the group A are ethynyl, prop-1-yn-1-yl, but-1-yn-1-yl, cyano,
cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy.
[0082] The group B preferably denotes
tri-(C.sub.1-4-alkyl)silyl-C.sub.1-6-alkyl, C.sub.2-6-alkyn-1-yl,
C.sub.2-6-alken-1-yl, amino, C.sub.1-3-alkylamino,
di-(C.sub.1-3-alkyl)amino, pyrrolidin-1-yl, pyrrolidin-2-on-1-yl,
piperidin-1-yl, piperidin-2-on-1-yl, morpholin-4-yl,
morpholin-3-on-4-yl, piperazin-1-yl,
4-(C.sub.1-3-alkyl)piperazin-1-yl, nitro, C.sub.3-7-cycloalkyloxy,
C.sub.5-7-cycloalkenyloxy, C.sub.3-7-cycloalkylsulphanyl,
C.sub.3-7-cycloalkylsulphinyl, C.sub.3-7-cycloalkylsulphonyl,
C.sub.5-7-cycloalkenylsulphanyl, C.sub.5-7-cycloalkenylsulphinyl,
C.sub.5-7-cycloalkenylsulphonyl,
while the above-mentioned alkynyl and alkenyl groups may be mono-
or polysubstituted by fluorine or chlorine, preferably fluorine,
and the above-mentioned alkynyl and alkenyl groups may be mono- or
disubstituted by identical or different groups L1; the
above-mentioned cycloalkyl and cycloalkenyl rings may be mono- or
disubstituted independently of one another by substituents selected
from fluorine and C.sub.1-3-alkyl, and in the above-mentioned
cycloalkyl and cycloalkenyl rings one or two methylene groups may
be replaced independently of one another by O, S, CO, SO, SO.sub.2
or NR.sup.N, preferably O, CO, S, SO.sub.2 or NR.sup.N, most
particularly preferably by O or CO.
[0083] Particularly preferably the group B denotes
tri-(C.sub.1-4-alkyl)silyl-C.sub.1-6-alkyl, C.sub.2-6-alkyn-1-yl,
C.sub.2-6-alken-1-yl, nitro, C.sub.3-7-cycloalkyloxy,
C.sub.5-7-cycloalkenyloxy, C.sub.3-7-cycloalkylsulphanyl,
C.sub.3-7-cycloalkylsulphinyl, C.sub.3-7-cycloalkylsulphonyl,
C.sub.5-7-cycloalkenylsulphanyl, C.sub.5-7-cycloalkenylsulphinyl,
C.sub.5-7-cycloalkenylsulphonyl,
while the above-mentioned alkynyl and alkenyl groups may be mono-
or polysubstituted by fluorine or chlorine, preferably fluorine,
and the above-mentioned alkynyl and alkenyl groups may be mono- or
disubstituted by identical or different groups L1; while the
above-mentioned cycloalkyl and cycloalkenyl rings may be mono- or
disubstituted independently of one another by substituents selected
from fluorine and C.sub.1-3-alkyl, and in the above-mentioned
cycloalkyl and cycloalkenyl rings one or two methylene groups may
be replaced independently of one another by O, S, CO, SO, SO.sub.2
or NR.sup.N, preferably O, CO, S, SO.sub.2 or NR.sup.N, most
particularly preferably by O or CO.
[0084] Most particularly preferably the group B denotes
tri-(C.sub.1-4-alkyl)silyl-C.sub.1-6-alkyl, C.sub.2-6-alkyn-1-yl,
C.sub.2-6-alken-1-yl, C.sub.3-7-cycloalkyloxy,
C.sub.5-7-cycloalkenyloxy, C.sub.3-7-cycloalkylsulphanyl,
C.sub.5-7-cycloalkenylsulphanyl, while the above-mentioned alkynyl
and alkenyl groups may be mono- or polysubstituted by fluorine or
monosubstituted by chlorine or the group L1, and in the cycloalkyl
and cycloalkenyl groups one or two methylene groups may be replaced
independently of one another by O, CO, S, SO.sub.2 or NR.sup.N,
particularly O or CO.
[0085] Examples of most particularly preferred definitions of the
group B are trimethylsilylethyl, ethynyl, 1-propyn-1-yl,
1-butyn-1-yl, tert.-butylethynyl, 2-hydroxyprop-2-ylethynyl,
2-methoxyprop-2-ylethynyl, 3-hydroxy-1-propyn-1-yl,
3-methoxy-1-propyn-1-yl, ethenyl, 1-propenyl, 1-butenyl,
tert.-butylethenyl, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy,
cyclohexyloxy, tetrahydrofuranyloxy, tetrahydrothiophenyloxy,
1,1-dioxotetrahydrothiophenyloxy, tetrahydropyranyloxy,
tetrahydrothiopyranyloxy, 1,1-dioxotetrahydrothiopyranyloxy,
tetrahydrofuranonyloxy, piperidinyloxy, piperidinonyloxy,
pyrrolidin-3-yloxy, pyrrolidinon-3-yloxy,
tetrahydrofuranyl-sulphanyl, cyclopropylsulphanyl,
cyclobutylsulphanyl, cyclopentyl-sulphanyl and cyclohexylsulphanyl,
while the --NH group in a piperidinyl, piperidinonyl, pyrrolidinyl
or pyrrolidinonyl ring may be substituted by R.sup.N, particularly
C.sub.1-3-alkyl or acetyl.
[0086] Most particularly preferred meanings are
trimethylsilylethyl, ethynyl, 2-hydroxyprop-2-ylethynyl,
2-methoxyprop-2-ylethynyl, 3-hydroxy-1-propyn-1-yl,
3-methoxy-1-propyn-1-yl, cyclopropyloxy, cyclobutyloxy,
cyclopentyloxy, cyclohexyloxy, tetrahydrofuran-3-yloxy,
tetrahydropyran-4-yloxy, piperidin-4-yloxy,
N-methylpiperidin-4-yloxy and N-acetylpiperidin-4-yloxy. Examples
which deserve special mention are ethynyl, trimethylsilylethyl,
cyclobutyloxy, cyclopentyloxy, cyclohexyloxy,
tetrahydrofuran-3-yloxy and tetrahydropyran-4-yloxy.
[0087] If in the residues or groups A, B, R.sup.1 or R.sup.3 there
are cycloalkyl or cycloalkenyl rings wherein two methylene groups
are replaced by O, S or NR.sup.N or are replaced by S, NR.sup.N,
CO, SO or SO.sub.2, these methylene groups are preferably not
directly connected to one another. If however two methylene groups
are replaced by O and CO or by NR.sup.N and CO, these may be
directly connected to one another, so as to form a --O--CO-- or
--NR.sup.N--CO group.
[0088] Preferred meanings of the group L1 are selected from among
hydroxy, cyano, C.sub.3-6-cycloalkyl, C.sub.1-4-alkylcarbonyl,
aminocarbonyl, C.sub.1-4-alkylaminocarbonyl,
di-(C.sub.1-3-alkyl)aminocarbonyl, pyrrolidin-1-ylcarbonyl,
piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl,
C.sub.1-4-alkoxycarbonyl, C.sub.1-4-alkyloxy,
C.sub.1-4-alkylsulphanyl, C.sub.1-4-alkylsulphinyl, and
C.sub.1-4-alkylsulphonyl.
[0089] Particularly preferred meanings of the group L1 are selected
from among hydroxy, C.sub.1-4-alkyloxy and
C.sub.1-4-alkylsulphanyl.
[0090] If L1 denotes hydroxy, the hydroxy group is not directly
linked to a C atom of a double or triple bond.
[0091] Compounds according to a first embodiment of this invention
may be described by general formula I, particularly formulae I.1
and I.2, particularly preferably formula I.2, wherein
R.sup.3 is selected from one of the definitions of the group B
given hereinbefore and the other groups and substituents are
defined as hereinbefore and hereinafter, including the tautomers,
the stereoisomers thereof, the mixtures thereof and the salts
thereof.
[0092] According to this embodiment preferred meanings of the group
R.sup.1 are hydrogen, fluorine, chlorine, bromine, iodine,
C.sub.1-4-alkyl, C.sub.2-6-alkynyl, C.sub.1-4-alkoxy,
C.sub.2-4-alkenyl-C.sub.1-4-alkoxy,
C.sub.2-4-alkynyl-C.sub.1-4-alkoxy, methyl substituted by 1 to 3
fluorine atoms, ethyl substituted by 1 to 5 fluorine atoms, methoxy
substituted by 1 to 3 fluorine atoms, ethoxy substituted by 1 to 5
fluorine atoms, C.sub.1-4-alkyl substituted by a hydroxy or
C.sub.1-3-alkoxy group, C.sub.2-4-alkoxy substituted by a hydroxy
or C.sub.1-3-alkoxy group, C.sub.2-6-alkenyl, C.sub.3-6-cycloalkyl,
C.sub.3-6-cycloalkyl-C.sub.1-3-alkyl, C.sub.3-7-cycloalkyloxy,
C.sub.3-6-cycloalkyl-C.sub.1-3-alkoxy, C.sub.5-7-cycloalkenyloxy,
hydroxy, amino, nitro or cyano, while in the C.sub.5-6-cycloalkyl
groups a methylene group may be replaced by O.
[0093] Particularly preferred meanings are hydrogen, fluorine,
chlorine, bromine, cyano, methyl, ethyl, isopropyl, difluoromethyl,
trifluoromethyl, ethynyl, prop-1-yn-1-yl, but-1-yn-1-yl, hydroxy,
methoxy, ethoxy, difluoromethoxy, cyclopropyloxy, cyclobutyloxy,
cyclopentyloxy, cyclohexyloxy, particularly methyl and
chlorine.
[0094] Compounds according to a second embodiment of this invention
may be described by general formula I, particularly formulae I.1
and I.2, particularly preferably formula I.2, wherein
R.sup.1 is selected from the definitions of the group A given
hereinbefore and the other groups and substituents are defined as
hereinbefore and hereinafter, including the tautomers, the
stereoisomers thereof, the mixtures thereof and the salts
thereof.
[0095] According to this second embodiment preferred meanings of
the group R.sup.3 are hydrogen, fluorine, chlorine, bromine,
hydroxy, cyano, C.sub.1-6-alkyl, trimethylsilylethyl,
C.sub.2-6-alkenyl, C.sub.2-6-alkynyl, difluoromethyl,
trifluoromethyl, C.sub.3-7-cycloalkyl, C.sub.5-7-cycloalkenyl,
C.sub.1-6-alkyloxy, difluoromethoxy, trifluoromethoxy,
pentafluorethoxy, C.sub.3-7-cycloalkyloxy, tetrahydrofuranyloxy,
tetrahydrofuranonyloxy, C.sub.1-6-alkylsulphanyl,
cyclopropylidenemethyl, aryl or heteroaryl.
[0096] According to this second embodiment particularly preferred
meanings of the group R.sup.3 are hydrogen, fluorine, chlorine,
methyl, ethyl, isopropyl, tert.-butyl, ethynyl, 1-propynyl,
trimethylsilylethyl, difluoromethyl, trifluoromethyl, cyclopropyl,
cyclobutyl, cyclopentyl, methoxy, ethoxy, isopropoxy,
cyclopentyloxy, difluoromethoxy, trifluoromethoxy,
pentafluorethoxy, tetrahydrofuran-3-yloxy,
tetrahydrofuran-2-on-3-yloxy, methylsulphanyl, ethylsulphanyl,
isopropylsulphanyl, cyclopropylidenemethyl, phenyl, fluorophenyl,
pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, imidazolyl,
pyrazolyl, triazolyl, tetrazolyl, oxazolyl, oxadiazolyl, thiazolyl
or thiadiazolyl.
[0097] According to this second embodiment most particularly
preferred meanings of the group R.sup.3 are hydrogen, fluorine,
chlorine, methyl, ethyl, isopropyl, tert.-butyl, ethynyl,
1-propynyl, trimethylsilylethyl, difluoromethyl, trifluoromethyl,
cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, isopropoxy,
cyclopentyloxy, difluoromethoxy, trifluoromethoxy,
pentafluorethoxy, tetrahydrofuran-3-yloxy,
tetrahydrofuran-2-on-3-yloxy, methylsulphanyl, ethylsulphanyl,
isopropylsulphanyl, cyclopropylidenemethyl. Examples of such
particularly preferred meanings are methyl, ethyl, methoxy, ethoxy,
trimethylsilylethyl, ethynyl, cyclopentyloxy,
tetrahydrofuran-3-yloxy, tetrahydrofuran-2-on-3-yloxy, particularly
trimethylsilylethyl, ethoxy, cyclopentyloxy and
tetrahydrofuran-3-yloxy.
[0098] Meanings of other groups and substituents will now be given
which are to be regarded as preferred according to general formula
I, formulae I.1 and I.2 and also according to the embodiments
described hereinbefore:
[0099] Preferred meanings of the group R.sup.2 are hydrogen,
fluorine, chlorine, bromine, methyl, hydroxy, methoxy, ethoxy,
trifluoromethoxy, cyano, nitro and methyl substituted by 1 to 3
fluorine atoms.
[0100] Particularly preferred meanings of the group R.sup.2 are
hydrogen, fluorine, hydroxy, methoxy, ethoxy and methyl,
particularly hydrogen and methyl.
[0101] Preferred meanings of the group R.sup.4 are hydrogen and
fluorine, particularly hydrogen.
[0102] Preferred meanings of the group R.sup.5 are hydrogen and
fluorine, particularly hydrogen.
[0103] The group R.sup.N preferably denotes H, methyl, ethyl or
acetyl.
[0104] The group R.sup.6 preferably denotes according to the
invention hydrogen, (C.sub.1-8-alkyl)oxycarbonyl,
C.sub.1-8-alkylcarbonyl or benzoyl, particularly hydrogen or
(C.sub.1-6-alkyl)oxycarbonyl, C.sub.1-6-alkylcarbonyl, particularly
preferably hydrogen, methylcarbonyl, methoxycarbonyl or
ethoxycarbonyl, most particularly preferably hydrogen or
methoxycarbonyl.
[0105] The substituents R.sup.7a, R.sup.7b, R.sup.7c preferably
represent independently of one another hydrogen,
(C.sub.1-8-alkyl)oxycarbonyl, (C.sub.1-18-alkyl)carbonyl, benzoyl,
particularly hydrogen or (C.sub.1-6-alkyl)oxycarbonyl,
(C.sub.1-8-alkyl)carbonyl, particularly preferably hydrogen,
methoxycarbonyl, ethoxycarbonyl, methylcarbonyl or ethylcarbonyl.
Most particularly preferably R.sup.7a, R.sup.7b and R.sup.7c
represent hydrogen.
[0106] The compounds of formula I wherein R.sup.6, R.sup.7a,
R.sup.7b and R.sup.7c according to the invention have a meaning
other than hydrogen, for example C.sub.1-8-alkylcarbonyl, are
preferably suitable as intermediate products for the synthesis of
compounds of formula I wherein R.sup.7a, R.sup.7b and R.sup.7c
denote hydrogen.
[0107] Particularly preferred compounds of general formula I are
selected from among formulae I.2a to I.2d, particularly I.2c:
##STR00011##
while the groups R.sup.1 to R.sup.6 and R.sup.7a, R.sup.7b,
R.sup.7c have one of the meanings given previously, particularly
have one of the meanings given specified as being preferred; and
particularly [0108] R.sup.1 denotes hydrogen, fluorine, chlorine,
bromine, iodine, C.sub.1-4-alkyl, C.sub.2-6-alkynyl,
C.sub.1-4-alkoxy, C.sub.2-4-alkenyl-C.sub.1-4-alkoxy,
C.sub.2-4-alkynyl-C.sub.1-4-alkoxy, methyl substituted by 1 to 3
fluorine atoms, ethyl substituted by 1 to 5 fluorine atoms, methoxy
substituted by 1 to 3 fluorine atoms, ethoxy substituted by 1 to 5
fluorine atoms, C.sub.1-4-alkyl substituted by a hydroxy or
C.sub.1-3-alkoxy group, C.sub.2-4-alkoxy substituted by a hydroxy
or C.sub.1-3-alkoxy group, C.sub.2-6-alkenyl, C.sub.3-6-cycloalkyl,
C.sub.3-6-cycloalkyl-C.sub.1-3-alkyl, C.sub.3-7-cycloalkyloxy,
C.sub.3-6-cycloalkyl-C.sub.1-3-alkoxy, C.sub.5-7-cycloalkenyloxy,
hydroxy, amino, nitro or cyano, while in the C.sub.5-6-cycloalkyl
groups a methylene group may be replaced by O; particularly
preferably denotes hydrogen, fluorine, chlorine, bromine, cyano,
methyl, ethyl, isopropyl, difluoromethyl, trifluoromethyl, ethynyl,
prop-1-yn-1-yl, but-1-yn-1-yl, hydroxy, methoxy, ethoxy,
difluoromethoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy or
cyclohexyloxy; and [0109] R.sup.2 denotes hydrogen, fluorine,
hydroxy, methoxy, ethoxy or methyl, particularly hydrogen or
methyl; and [0110] R.sup.3 is selected from the group B consisting
of trimethylsilylethyl, ethynyl, 1-propyn-1-yl, 1-butyn-1-yl,
tert.-butylethynyl, 2-hydroxyprop-2-ylethynyl,
2-methoxyprop-2-ylethynyl, 3-hydroxy-1-propyn-1-yl,
3-methoxy-1-propyn-1-yl, ethenyl, 1-propenyl, 1-butenyl,
tert.-butylethenyl, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy,
cyclohexyloxy, tetrahydrofuranyloxy, tetrahydrothiophenyloxy,
1,1-dioxotetrahydrothiophenyloxy, tetrahydropyranyloxy,
tetrahydrothiopyranyloxy, 1,1-dioxotetrahydrothiopyranyloxy,
tetrahydrofuranonyloxy, piperidinyloxy, piperidinonyloxy,
pyrrolidin-3-yloxy, pyrrolidinone-3-yloxy,
tetrahydrofuranyl-sulphanyl, cyclopropylsulphanyl,
cyclobutylsulphanyl, cyclopentylsulphanyl and cyclohexylsulphanyl,
while the --NH group in a piperidinyl, piperidinonyl, pyrrolidinyl
or pyrrolidinonyl ring may be substituted by R.sup.N, particularly
C.sub.1-3-alkyl or acetyl; is particularly preferably selected from
trimethylsilylethyl, ethynyl, 2-hydroxyprop-2-ylethynyl,
2-methoxyprop-2-ylethynyl, 3-hydroxy-1-propyn-1-yl,
3-methoxy-1-propyn-1-yl, cyclopropyloxy, cyclobutyloxy,
cyclopentyloxy, cyclohexyloxy, tetrahydrofuran-3-yloxy,
tetrahydropyran-4-yloxy, piperidin-4-yloxy,
N-methylpiperidin-4-yloxy and N-acetylpiperidin-4-yloxy; and [0111]
R.sup.4 denotes hydrogen or fluorine, particularly hydrogen; and
[0112] R.sup.5 denotes hydrogen or fluorine, particularly hydrogen;
and [0113] R.sup.6 denotes hydrogen, (C.sub.1-6-alkyl)oxycarbonyl,
(C.sub.1-6-alkyl)carbonyl or benzoyl, particularly hydrogen,
methylcarbonyl, methoxycarbonyl or ethoxycarbonyl, most
particularly preferably hydrogen; and [0114] R.sup.7a, R.sup.7b,
R.sup.7c independently of one another represent hydrogen,
(C.sub.1-6-alkyl)oxycarbonyl, (C.sub.1-8-alkyl)carbonyl or benzoyl,
particularly hydrogen, methoxycarbonyl, ethoxycarbonyl,
methylcarbonyl or ethylcarbonyl, particularly preferably hydrogen;
including the tautomers, the stereoisomers, the mixtures thereof
and the salts thereof.
[0115] According to a variant of the embodiments given
hereinbefore, other preferred compounds are those wherein the
phenyl group which carries the substituent R.sup.3 has at least one
other substituent R.sup.4 and/or R.sup.5 which is different from
hydrogen. According to this variant, particularly preferred
compounds are those which have a substituent R.sup.4 representing
fluorine.
[0116] The phenyl group which carries the substituent R.sup.3 is
preferably at most monofluorinated.
[0117] The compounds of general formula I specified in the
experimental section that follows, and the derivatives thereof,
wherein R.sup.6 has a meaning according to the invention other than
hydrogen, particularly wherein R.sup.6 denotes ethoxycarbonyl or
methoxycarbonyl, including the tautomers, the stereoisomers thereof
and the mixtures thereof, are preferred according to the
invention.
[0118] Particularly preferred compounds of general formula I are
selected from among [0119] (1)
1-chloro-2-(4-cyclopentyloxybenzyl)-4-(.beta.-D-glucopyranos-1-yl)-benzen-
e [0120] (2)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy-
)-benzyl]-benzene [0121] (3)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy-
)-benzyl]-benzene [0122] (4)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(tetrahydrofuran-2-on-3-ylox-
y)-benzyl]-benzene [0123] (5)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-cyclobutyloxy-benzyl)-benzen-
e [0124] (6)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-cyclohexyloxy-benzyl)-benzen-
e [0125] (7)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(tetrahydropyran-4-yloxy)-be-
nzyl]-benzene [0126] (8)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(1-acetyl-piperidin-4-yloxy)-
-benzyl]-benzene [0127] (10)
1-(.beta.-D-Glucopyranos-1-yl)-4-methyl-3-[4-(tetrahydrofuran-3-yloxy)-be-
nzyl]-benzene [0128] (11)
1-(.beta.-D-Glucopyranos-1-yl)-4-methyl-3-[4-(2-trimethylsilyl-ethyl)-ben-
zyl]-benzene [0129] (12)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene
[0130] (13)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(piperidin-4-yloxy)-benzyl]--
benzene [0131] (14)
1-fluoro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene
[0132] (15)
1-(.beta.-D-glucopyranos-1-yl)-3-(4-ethynyl-benzyl)-benzene [0133]
(16)
1-ethynyl-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethoxy-benzyl)-benzene
[0134] (17)
1-methoxy-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene
and the derivatives thereof wherein R.sup.6 has a meaning according
to the invention other than hydrogen, particularly wherein R.sup.6
denotes ethoxycarbonyl or methoxycarbonyl, including the tautomers,
the stereoisomers thereof and the mixtures thereof.
[0135] In the processes according to the invention the groups
R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 preferably have the
meanings specified hereinbefore as being preferred. Moreover R'
preferably denotes H, C.sub.1-3-alkyl or benzyl, particularly H,
ethyl or methyl. The groups R.sup.8a, R.sup.8b, R.sup.8c and
R.sup.8d independently of one another preferably denote H,
C.sub.1-4-alkylcarbonyl or benzyl, particularly H, methylcarbonyl,
ethylcarbonyl or benzyl.
[0136] The invention also relates to compounds of general formula
IV, particularly of general formula IV'
##STR00012##
wherein Hal denotes chlorine, bromine or iodine and the groups
R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are as hereinbefore defined
and the group R.sup.3 is selected from the group B, as intermediate
products or starting materials in the synthesis of the compounds
according to the invention. Particularly preferably, the groups
R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings
given after formulae I.2a to I.2d. Most particularly preferred are
compounds of general formula IV', wherein Hal denotes chlorine,
bromine or iodine and the groups R.sup.1, R.sup.2, R.sup.4 and
R.sup.5 have the meanings given after formulae I.2a to I.2d and the
group R.sup.3 denotes ethynyl or C.sub.3-6-1-alkyn-1-yl, while the
ethynyl group may be substituted by the group --SiR.sub.3, while
the groups R independently of one another represent
C.sub.1-4-alkyl, C.sub.1-4-alkoxy or aryl, and the
C.sub.3-6-1-alkyn-1-yl group may be substituted by hydroxy or
C.sub.1-3-alkoxy, particularly hydroxy or methoxy.
[0137] The invention also relates to compounds of general formula
II, particularly of general formula II'
##STR00013##
wherein R', R.sup.8a, R.sup.8b, R.sup.8c, R.sup.8d, R.sup.1,
R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined as hereinbefore
and hereinafter; particularly wherein R' denotes H, C.sub.1-3-alkyl
or benzyl, particularly H, ethyl or methyl; and the groups
R.sup.8a, R.sup.8b, R.sup.8c and R.sup.8d independently of one
another represent H, C.sub.1-4-alkylcarbonyl or benzyl,
particularly H, methylcarbonyl, ethylcarbonyl or benzyl and the
groups R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are as hereinbefore
defined and the group R.sup.3 is selected from the group B, as
intermediate products or starting materials in the synthesis of the
compounds according to the invention. Particularly preferably the
groups R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the
meanings given following formulae I.2a to I.2d.
[0138] Some terms used above and hereinafter to describe the
compounds according to the invention will now be defined more
closely.
[0139] The term halogen denotes an atom selected from the group
consisting of F, Cl, Br and I, particularly F, Cl and Br.
[0140] The term C.sub.1-n-alkyl, wherein n may have a value of 1 to
18, denotes a saturated, branched or unbranched hydrocarbon group
with 1 to n C atoms. Examples of such groups include methyl, ethyl,
n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl,
n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, n-hexyl, iso-hexyl,
etc.
[0141] The term C.sub.2-n-alkynyl, wherein n has a value of 3 to 6,
denotes a branched or unbranched hydrocarbon group with 2 to n C
atoms and a C.ident.C triple bond. Examples of such groups include
ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl,
1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl,
2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl etc. Unless otherwise
stated alkynyl groups are connected to the remainder of the
molecule via the C atom in position 1. Therefore terms such as
1-propynyl, 2-propynyl, 1-butynyl, etc. are equivalent to the terms
1-propyn-1-yl, 2-propyn-1-yl, 1-butyn-1-yl, etc. This also applies
analogously to C.sub.2-n-alkenyl groups.
[0142] The term C.sub.1-n-alkoxy denotes a C.sub.1-n-alkyl-O group,
wherein C.sub.1-n-alkyl is as hereinbefore defined. Examples of
such groups include methoxy, ethoxy, n-propoxy, iso-propoxy,
n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentoxy,
iso-pentoxy, neo-pentoxy, tert-pentoxy, n-hexoxy, iso-hexoxy
etc.
[0143] The term C.sub.1-n-alkylcarbonyl denotes a
C.sub.1-n-alkyl-C(.dbd.O) group, wherein C.sub.1-n-alkyl is as
hereinbefore defined. Examples of such groups include
methylcarbonyl, ethylcarbonyl, n-propylcarbonyl,
iso-propylcarbonyl, n-butylcarbonyl, iso-butylcarbonyl,
sec-butylcarbonyl, tert-butylcarbonyl, n-pentylcarbonyl,
iso-pentylcarbonyl, neo-pentylcarbonyl, tert-pentylcarbonyl,
n-hexylcarbonyl, iso-hexylcarbonyl, etc.
[0144] The term C.sub.3-n-cycloalkyl denotes a saturated mono-,
bi-, tri- or spirocarbocyclic group with 3 to n C atoms. Examples
of such groups include cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl,
bicyclo[3.2.1.]octyl, spiro[4.5]decyl, norpinyl, norbonyl,
norcaryl, adamantyl, etc. Preferably the term C.sub.3-7-cycloalkyl
denotes saturated monocyclic groups.
[0145] The term C.sub.5-n-cycloalkenyl denotes a
C.sub.5-n-cycloalkyl group which is as hereinbefore defined and
additionally has at least one unsaturated C.dbd.C double bond.
[0146] The term C.sub.3-n-cycloalkylcarbonyl denotes a
C.sub.3-n-cycloalkyl-C(.dbd.O) group wherein C.sub.3-n-cycloalkyl
is as hereinbefore defined.
[0147] The term tri-(C.sub.1-4-alkyl)silyl comprises silyl groups
which have identical or two or three different alkyl groups.
[0148] The term di-(C.sub.1-3-alkyl)amino comprises amino groups
which have identical or two different alkyl groups.
[0149] The style used above and hereinafter, in which a bond of a
substituent in a phenyl group is shown towards the centre of the
phenyl ring, denotes, unless otherwise stated, that this
substituent may be bound to any free position of the phenyl ring
bearing an H atom.
[0150] The compounds according to the invention may be obtained
using methods of synthesis known in principle. Preferably the
compounds are obtained by the following methods according to the
invention which are described in more detail hereinafter.
[0151] The glucose derivatives of formula II according to the
invention may be synthesised from D-gluconolactone or a derivative
thereof by adding the desired benzylbenzene compound in the form of
an organometallic compound (Diagram 1).
##STR00014##
[0152] The reaction according to Diagram 1 is preferably carried
out starting from a halo-benzylbenzene compound of general formula
IV, wherein Hal denotes chlorine, bromine or iodine. Starting from
the haloaromatic compound IV the corresponding organometallic
compound (V) may be prepared either by means of a so-called
halogen-metal exchange or by inserting the metal into the
carbon-halogen bond. The halogen-metal exchange with bromine or
iodine-substituted aromatic groups may be carried out for example
with an organolithium compound such as e.g. n-, sec- or
tert-butyllithium and thereby yields the corresponding lithiated
aromatic group. The analogous magnesium compound may also be
generated by a halogen-metal exchange with a suitable Grignard
compound such as e.g. isopropylmagnesium bromide or
diisopropylmagnesium. The reactions are preferably carried out
between 0 and -100.degree. C., particularly preferably between -10
and -80.degree. C., in an inert solvent or mixtures thereof, such
as for example diethyl ether, tetrahydrofuran, toluene, hexane or
methylene chloride. The magnesium or lithium compounds thus
obtained may optionally be transmetallised with metal salts such as
e.g. cerium trichloride, to form additional organometallic
compounds (V) suitable for addition. Alternatively the
organometallic compound (V) may also be prepared by inserting a
metal into the carbon-halogen bond of the haloaromatic compound IV.
Metals such as e.g. lithium or magnesium are suitable for this. The
addition of the organometallic compound V to gluconolactone or
derivatives thereof of formula VI is preferably carried out at
temperatures between 0 and -100.degree. C., particularly preferably
at -30 to -80.degree. C., in an inert solvent or mixtures thereof,
to obtain the compound of formula II. The lithiation and/or
coupling reaction may also be carried out in microreactors and/or
micromixers in order to avoid low temperatures; for example
analogously to the processes described in WO 2004/076470.
[0153] Suitable solvents are e.g. diethyl ether, toluene, methylene
chloride, hexane, tetrahydrofuran or mixtures thereof. The
reactions may be carried out without any further adjuvants or in
the case of unreactive coupling partners in the presence of Lewis
acids such as e.g. BF.sub.3*OEt.sub.2 or Me.sub.3SiCl (see M.
Schlosser, Organometallics in Synthesis, John Wiley & Sons,
Chichester/New York/Brisbane/Toronto/Singapore, 1994). Preferred
definitions of the groups R.sup.8a, R.sup.8b, R.sup.8c and R.sup.8d
are benzyl, substituted benzyl, trialkylsilyl, particularly
preferably trimethylsilyl, triisopropylsilyl, 4-methoxybenzyl and
benzyl. If two adjacent groups of the group consisting of R.sup.8a,
R.sup.8b, R.sup.8c and R.sup.8d are linked together, these two
groups are preferably part of a benzylideneacetal,
4-methoxybenzylideneacetal, isopropylketal or constitute a
2,3-dimethoxy-butylene group which is linked via the 2 and 3
positions of the butane with the adjacent oxygen atoms of the
pyranose ring. The group R' preferably denotes hydrogen or
C.sub.1-4-alkyl, particularly preferably hydrogen, methyl or ethyl.
The group R' is inserted after the addition of the organometallic
compound V or a derivative thereof to the gluconolactone VI. For
this purpose the reaction solution is treated with an alcohol such
as e.g. methanol or ethanol or water in the presence of an acid
such as e.g. methanesulphonic acid, toluenesulphonic acid,
sulphuric acid or hydrochloric acid.
[0154] The synthesis of haloaromatic compound of formula IV may be
carried out using standard transformations in organic chemistry or
at least methods known from the specialist literature in organic
synthesis (see inter alia J. March, Advanced Organic Reactions,
Reactions, Mechanisms, and Structure, 4th Edition, John Wiley &
Sons, Chichester/New York/Brisbane/Toronto/Singapore, 1992 and
literature cited therein). The synthesis strategies described in
the following provide a demonstration of this, by way of
example.
##STR00015##
[0155] Synthesis strategy 1 (Diagram 2) shows the preparation of
the haloaromatic compound of formula II starting from a
benzoylchloride and a second aromatic group which is converted by
Friedel-Crafts acylation into the diphenylketone derivative. This
classic reaction has a wide substrate breadth and is carried out in
the presence of a catalyst which is used in catalytic or
stoichiometric amounts, such as e.g. AlCl.sub.3, FeCl.sub.3,
iodine, iron, ZnCl.sub.2, sulphuric acid or
trifluoromethanesulphonic acid. Instead of the carboxylic acid
chloride it is also possible to use the carboxylic acid, an
anhydride or ester thereof or the corresponding benzonitrile. The
reactions are preferably carried out in chlorinated hydrocarbons
such as e.g. dichloromethane and 1,2-dichloroethane at temperatures
from -30 to 120.degree. C., preferably at 30 to 100.degree. C.
However, solvent-free reactions or reactions in a microwave oven
are also possible. In a second reaction step the diphenylketone is
reduced to the diphenylmethane. This reaction may be carried out in
two steps via the corresponding diphenylmethanol or in one step. In
the two-step variant the ketone is reduced with a reducing agent
such as for example a metal hydride such as e.g. NaBH.sub.4,
LiAlH.sub.4 or iBu.sub.2AIH to form the alcohol. The resulting
alcohol can be converted in the presence of a Lewis acid such as
for example BF.sub.3*OEt.sub.2, trifluoroacetic acid, InCl.sub.3 or
AlCl.sub.3 with a reducing agent such as e.g. Et.sub.3SiH,
NaBH.sub.4, or Ph.sub.2SiClH to form the desired diphenylmethane.
The one-step process starting from the ketone to obtain the
diphenylmethane may be carried out e.g. with a silane such as e.g.
Et.sub.3SiH, a borohydride such as e.g. NaBH.sub.4 or an aluminium
hydride such as LiAlH.sub.4 in the presence of a Lewis acid such as
for example BF.sub.3*OEt.sub.2, tris(pentafluorophenyl)-borane,
trifluoroacetic acid, aluminium chloride or InCl.sub.3. The
reactions are preferably carried out in solvents such as e.g.
halogenated hydrocarbons such as dichloromethane, toluene or
acetonitrile at temperatures of -30 to 150.degree. C., preferably
at 20 to 100.degree. C. Reductions with hydrogen in the presence of
a transition metal catalyst such as e.g. Pd on charcoal are another
possible method of synthesis. Reductions according to Wolff-Kishner
or variants thereof are also possible. The ketone is first of all
converted with hydrazine or a derivative thereof, such as e.g.
1,2-bis(tert-butyldimethylsilyl)hydrazine, into the hydrazone which
breaks down under strongly basic reaction conditions and heating to
form the diphenylmethane and nitrogen. The reaction may be carried
out in one reaction step or after isolation of the hydrazone or a
derivative thereof in two separaten reaction steps. Suitable bases
include e.g. KOH, NaOH or KOtBu in solvents such as e.g.
ethyleneglycol, toluene, DMSO, 2-(2-butoxyethoxy)ethanol or
t-butanol; solvent-free reactions are also possible. The reactions
may be carried out at temperatures between 20 to 250.degree. C.,
preferably between 80 to 200.degree. C. An alternative to the basic
conditions of the Wolff-Kishner reduction is the Clemmensen
reduction which takes place under acid conditions, which may also
be used here.
##STR00016##
[0156] The second synthesis strategy (Diagram 3) shows another
possible way of synthesising the halogen-aromatic groups of formula
II' illustrated by the example of a
trimethylsilylacetylene-substituted diphenylmethane. Starting from
an aromatic group which carries two groups selected from among
iodine, bromine, chlorine or sulphonate such as e.g.
trifluoromethylsulphonate, an alkyne group is attached via a
transition metal-catalysed monocoupling to the more reactive end of
the dihaloaromatic compound, the iodine-carbon bond (step 1). The
catalysts used are for example elemental palladium or nickel or
salts or complexes thereof. The reactions may be carried out with
the alkyne itself or metal acetylidene therefrom. If the alkyne
itself is used, coupling may be carried out in the presence of a
base such as e.g. NEt.sub.3 and a co-catalyst such as e.g. a copper
salt such as CuI (Sonogashira coupling). The reactions are not
limited to trimethylsilylacetylene, but allow the use of a number
of terminal alkynes. The reaction is extensively documented with
all its variations in the literature (see P. J. Stang, F.
Diederich, Metal-Catalyzed Cross-Coupling Reactions, Wiley-VCH,
Weinheim, 1997 and Angew. Chem. Int. Ed. 2003, 42, 1566-1568 and
literature cited therein). The other two steps for preparing the
diphenylmethane derivatives comprise transfunctionalising the
alkyne-substituted aromatic group to obtain a metallised (Mg, Li)
aromatic group which may be prepared, for example, by a
halogen-metal exchange as described hereinbefore (step 2). This
metallised aromatic compound which may be used directly or after
further transmetallation, is added to a benzaldehyde derivative.
This forms the diphenylmethanol shown in the diagram. Alternatively
it is also possible to use a benzoic acid derivative such as e.g. a
benzoic acid ester, anhydride, chloride or the acid itself or the
benzonitrile. Instead of the alcohol the corresponding ketone is
formed, which may also be obtained by Friedel-Crafts acylation as
described above. Further reaction of both the alcohol and the
ketone to form the diphenylmethane derivative has already been
described above (step 3). The trimethylsilylethynylated aromatic
halogen compound may however also be converted directly after
transmetallation into the desired product (step 4). For this, the
lithium or magnesium aromatic group obtained after a halogen-metal
exchange is reacted with a benzylelectrophil such as e.g. a benzyl
bromide or chloride. The reaction may be carried out without or,
better still, in the presence of a transition metal catalyst, such
as e.g. a copper salt or a palladium complex (see e.g. Org. Lett.
2001, 3, 2871-2874 and literature cited therein). The aromatic
lithium or magnesium group may however also be transmetallised
first, for example, to obtain the corresponding boric acids, boric
acid esters, stannanes, silanes or zinc compounds. Then it is
attached by means of a transition metal such as e.g. palladium,
nickel, rhodium, copper or iron to the benzyl group (see L.
Brandsma, S. F. Vasilevsky, H. D. Verkruijsse, Application of
Transition Metal Catalysts in Organic Synthesis, Springer-Verlag,
Berlin/Heidelberg, 1998). The reactions of the alkyne-substituted
aromatic group to the intermediate product of formula II' according
to steps 2 and 3 or step 4, which are illustrated by way of example
here for R.sup.3 denoting ethynyl or trimethylsilylethynyl, may
also be carried out analogously with other R.sup.3-substituted
aromatic groups.
##STR00017##
[0157] Synthesis strategy 3 (Diagram 4) shows an alternative form
of synthesis strategy 2, which is also illustrated using the
example of an aromatic trimethylsilylethynyl group II', but should
not be limited thereto. The synthesis starts with an aromatic group
which carries both a Hal group, which denotes a halogen atom
chlorine, bromine or iodine, or a pseudohalogen group, such as e.g.
trifluoromethanesulphonate, and also a metallic centre M, such as
e.g. a B(OH).sub.2, Si(OAlk).sub.3 or SnBu.sub.3 group. The two
centres thus "activated" may be exchanged chemoselectively one
after the other. Synthesis strategy 3 illustrates this with an
example in which first of all the halogen atom Hal is exchanged for
an alkyne substituent in a transition metal-catalysed reaction such
as e.g. the so-called Sonogashira coupling. In the second step the
metallic centre M is exchanged for a benzyl group which is
activated e.g. as the benzyl halide in another transition
metal-catalysed coupling, to obtain the desired product (see e.g.
Tetrahedron Lett. 2003, 44, 9255-9258 and literature cited
therein). Both steps may be carried out using transition metals
such as e.g. palladium, rhodium, nickel, copper or iron, or
complexes thereof. Both types of reaction are described in detail
in the literature. The method is not restricted to that shown here
but may also involve reversing the sequence of the two reaction
steps. In this case, the metallic centre M is first linked to the
benzyl group and then the halogen or pseudohalogen group Hal is
exchanged for the alkyne.
[0158] In order to prepare compounds of general formula I, in
process a) according to the invention, a compound of general
formula II
##STR00018##
wherein R', R.sup.1 to R.sup.5 are as hereinbefore defined and
R.sup.8a, R.sup.8b, R.sup.8c, R.sup.8d are as hereinbefore defined
and independently of one another represent for example acetyl,
pivaloyl, benzoyl, tert-butoxycarbonyl, benzyloxycarbonyl,
trialkylsilyl, benzyl or substituted benzyl or in each case two
adjacent groups R.sup.8a, R.sup.8b, R.sup.8c, R.sup.8d form a
benzylideneacetal or isopropylideneketal or a
2,3-dimethoxy-butylene group which is linked via position 2 and 3
of the butylene group to the oxygen atoms of the pyranose ring and
forms with them a substituted dioxane, which may be obtained as
hereinbefore described, is reacted with a reducing agent in the
presence of a Lewis or Bronsted acid.
[0159] Suitable reducing agents for the reaction include for
example silanes, such as triethyl, tripropyl, triisopropyl or
diphenylsilane, sodium borohydride, sodium cyanoborohydride, zinc
borohydride, boranes, lithium aluminium hydride,
diisobutylaluminium hydride or samarium iodide. The reductions are
carried out without or in the presence of a suitable Bronsted acid,
such as e.g. hydrochloric acid, toluenesulphonic acid,
trifluoroacetic acid or acetic acid, or Lewis acid, such as e.g.
boron trifluoride etherate, trimethylsilyltriflate, titaniium
tetrachloride, tin tetrachloride, scandium triflate or zinc iodide.
Depending on the reducing agent and the acid the reaction may be
carried out in a solvent, such as for example methylene chloride,
chloroform, acetonitrile, toluene, hexane, diethyl ether,
tetrahydrofuran, dioxane, ethanol, water or mixtures thereof at
temperatures between -60.degree. C. and 120.degree. C. One
particularly suitable combination of reagents consists for example
of triethylsilane and boron trifluoride etherate, which is
conveniently used in acetonitrile or dichloromethane at
temperatures of -60.degree. C. and 60.degree. C. Moreover, hydrogen
may be used in the presence of a transition metal catalyst, such as
e.g. palladium on charcoal or Raney nickel, in solvents such as
tetrahydrofuran, ethyl acetate, methanol, ethanol, water or acetic
acid, for the transformation described.
[0160] Alternatively, in order to prepare compounds of general
formula I according to process b) according to the invention, in a
compound of general formula III
##STR00019##
wherein R.sup.1 to R.sup.5 are as hereinbefore defined and R.sup.8a
to R.sup.8d denote one of the protective groups defined
hereinbefore, such as e.g. an acyl, arylmethyl, acetal, ketal or
silyl group, and which may be obtained for example by reduction
from the compound of formula II as hereinbefore described, the
protective groups are cleaved.
[0161] Any acyl protecting group used is cleaved for example
hydrolytically in an aqueous solvent, e.g. in water,
isopropanol/water, acetic acid/water, tetrahydrofuran/water or
dioxane/water, in the presence of an acid such as trifluoroacetic
acid, hydrochloric acid or sulphuric acid or in the presence of an
alkali metal base such as lithium hydroxide, sodium hydroxide or
potassium hydroxide or aprotically, e.g. in the presence of
iodotrimethylsilane, at temperatures between 0 and 120.degree. C.,
preferably at temperatures between 10 and 100.degree. C. A
trifluoroacetyl group is preferably cleaved by treating with an
acid such as hydrochloric acid, optionally in the presence of a
solvent such as acetic acid at temperatures between 50 and
120.degree. C. or by treating with sodium hydroxide solution
optionally in the presence of a solvent such as tetrahydrofuran or
methanol at temperatures between 0 and 50.degree. C.
[0162] Any acetal or ketal protecting group used is cleaved for
example hydrolytically in an aqueous solvent, e.g. in water,
isopropanol/water, acetic acid/water, tetrahydrofuran/water or
dioxane/water, in the presence of an acid such as trifluoroacetic
acid, hydrochloric acid or sulphuric acid or aprotically, e.g. in
the presence of iodotrimethylsilane, at temperatures between 0 and
120.degree. C., preferably at temperatures between 10 and
100.degree. C.
[0163] A trimethylsilyl group is cleaved for example in water, an
aqueous solvent mixture or a lower alcohol such as methanol or
ethanol in the presence of a base such as lithium hydroxide, sodium
hydroxide, potassium carbonate or sodium methoxide. In aqueous or
alcoholic solvents, acids such as e.g. hydrochloric acid,
trifluoroacetic acid or acetic acid are also suitable. For cleaving
in organic solvents, such as for example diethyl ether,
tetrahydrofuran or dichloromethane, it is also suitable to use
fluoride reagents, such as e.g. tetrabutylammonium fluoride.
[0164] A benzyl, methoxybenzyl or benzyloxycarbonyl group is
advantageously cleaved hydrogenolytically, e.g. with hydrogen in
the presence of a catalyst such as palladium/charcoal in a suitable
solvent such as methanol, ethanol, ethyl acetate or glacial acetic
acid, optionally with the addition of an acid such as hydrochloric
acid at temperatures between 0 and 100.degree. C., but preferably
at ambient temperatures between 20 and 60.degree. C., and at a
hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar. A
2,4-dimethoxybenzyl group, however, is preferably cleaved in
trifluoroacetic acid in the presence of anisole.
[0165] A tert.butyl or tert.butyloxycarbonyl group is preferably
cleaved by treating with an acid such as trifluoroacetic acid or
hydrochloric acid or by treating with iodotrimethylsilane
optionally using a solvent such as methylene chloride, dioxane,
methanol or diethylether.
[0166] In the reactions described hereinbefore, any reactive groups
present such as ethynyl, hydroxy, amino, alkylamino or imino groups
may be protected during the reaction by conventional protecting
groups which are cleaved again after the reaction.
[0167] For example, a protecting group for an ethynyl group may be
the trimethylsilyl or triisopropyl group. The 2-hydroxisoprop-2-yl
group may also be used as a protective group.
[0168] For example, a protecting group for a hydroxy group may be a
trimethylsilyl, acetyl, trityl, benzyl or tetrahydropyranyl
group.
[0169] Protecting groups for an amino, alkylamino or imino group
may be, for example, a formyl, acetyl, trifluoroacetyl,
ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl,
methoxybenzyl or 2,4-dimethoxybenzyl group.
[0170] Moreover, the compounds of general formula I obtained may be
resolved into their enantiomers and/or diastereomers, as mentioned
hereinbefore. Thus, for example, cis/trans mixtures may be resolved
into their cis and trans isomers, and compounds with at least one
optically active carbon atom may be separated into their
enantiomers.
[0171] Thus, for example, the cis/trans mixtures may be resolved by
chromatography into the cis and trans isomers thereof, the
compounds of general formula I obtained which occur as racemates
may be separated by methods known per se (cf. Allinger N. L. and
Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley
Interscience, 1971) into their optical antipodes and compounds of
general formula I with at least 2 asymmetric carbon atoms may be
resolved into their diastereomers on the basis of their
physical-chemical differences using methods known per se, e.g. by
chromatography and/or fractional crystallisation, and, if these
compounds are obtained in racemic form, they may subsequently be
resolved into the enantiomers as mentioned above.
[0172] The enantiomers are preferably separated by column
separation on chiral phases or by recrystallisation from an
optically active solvent or by reacting with an optically active
substance which forms salts or derivatives such as e.g. esters or
amides with the racemic compound, particularly acids and the
activated derivatives or alcohols thereof, and separating the
diastereomeric mixture of salts or derivatives thus obtained, e.g.
on the basis of their differences in solubility, whilst the free
antipodes may be released from the pure diastereomeric salts or
derivatives by the action of suitable agents. Optically active
acids in common use are e.g. the D- and L-forms of tartaric acid or
dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid,
mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid
or quinic acid. An optically active alcohol may be for example (+)
or (-)-menthol and an optically active acyl group in amides, for
example, may be a (+)- or (-)-menthyloxycarbonyl.
[0173] Furthermore, the compounds of formula I may be converted
into the salts thereof, particularly for pharmaceutical use into
the physiologically acceptable salts with inorganic or organic
acids. Acids which may be used for this purpose include for example
hydrochloric acid, hydrobromic acid, sulphuric acid,
methanesulphonic acid, phosphoric acid, fumaric acid, succinic
acid, lactic acid, citric acid, tartaric acid or maleic acid.
[0174] Moreover, the compounds obtained may be converted into
mixtures, for example 1:1 or 1:2 mixtures with amino acids,
particularly with alpha-amino acids such as proline or
phenylalanine, which may have particularly favourable properties
such as a high crystallinity.
[0175] The compounds according to the invention are advantageously
also obtainable using the methods described in the examples that
follow, which may also be combined for this purpose with methods
known to the skilled man from the literature, for example,
particularly the methods described in WO 98/31697, WO 01/27128, WO
02/083066, WO 03/099836 and WO 2004/063209.
[0176] As already mentioned, the compounds of general formula I
according to the invention and the physiologically acceptable salts
thereof have valuable pharmacological properties, particularly an
inhibitory effect on the sodium-dependent glucose cotransporter
SGLT, preferably SGLT2.
[0177] The biological properties of the new compounds may be
investigated as follows:
[0178] The ability of the substances to inhibit the SGLT-2 activity
may be demonstrated in a test set-up in which a CHO-K1 cell line
(ATCC No. CCL 61) or alternatively an HEK293 cell line (ATCC No.
CRL-1573), which is stably transfected with an expression vector
pZeoSV (Invitrogen, EMBL accession number L36849), which contains
the cDNA for the coding sequence of the human sodium glucose
cotransporter 2 (Genbank Acc. No. NM.sub.--003041) (CHO-hSGLT2 or
HEK-hSGLT2). These cell lines transport .sup.14C-labelled
alpha-methyl-glucopyranoside (.sup.14C-AMG, Amersham) into the
interior of the cell in sodium-dependent manner.
[0179] The SGLT-2 assay is carried out as follows:
[0180] CHO-hSGLT2 cells are cultivated in Ham's F12 Medium
(BioWhittaker) with 10% foetal calf serum and 250 .mu.g/ml zeocin
(Invitrogen), and HEK293-hSGLT2 cells are cultivated in DMEM medium
with 10% foetal calf serum and 250 .mu.g/ml zeocin (Invitrogen).
The cells are detached from the culture flasks by washing twice
with PBS and subsequently treating with trypsin/EDTA. After the
addition of cell culture medium the cells are centrifuged,
resuspended in culture medium and counted in a Casy cell counter.
Then 40,000 cells per well are seeded into a white, 96-well plate
coated with poly-D-lysine and incubated overnight at 37.degree. C.,
5% CO.sub.2. The cells are washed twice with 250 .mu.l of assay
buffer (Hanks Balanced Salt Solution, 137 mM NaCl, 5.4 mM KCl, 2.8
mM CaCl.sub.2, 1.2 mM MgSO.sub.4 and 10 mM HEPES (pH7.4), 50
.mu.g/ml of gentamycin). 250 .mu.l of assay buffer and 5 .mu.l of
test compound are then added to each well and the plate is
incubated for a further 15 minutes in the incubator. 5 .mu.l of 10%
DMSO are used as the negative control. The reaction is started by
adding 5 .mu.l of .sup.14C-AMG (0.05 .mu.Ci) to each well. After 2
hours' incubation at 37.degree. C., 5% CO.sub.2, the cells are
washed again with 250 .mu.l of PBS (20.degree. C.) and then lysed
by the addition of 25 .mu.l of 0.1 N NaOH (5 min. at 37.degree.
C.). 200 .mu.l of MicroScint20 (Packard) are added to each well and
incubation is continued for a further 20 min at 37.degree. C. After
this incubation the radioactivity of the .sup.14C-AMG absorbed is
measured in a Topcount (Packard) using a .sup.14C scintillation
program.
[0181] To determine the selectivity with respect to human SGLT1 an
analogous test is set up in which the cDNA for hSGLT1 (Genbank Acc.
No. NM000343) instead of hSGLT2 cDNA is expressed in CHO-K1 or
HEK293 cells.
[0182] The compounds of general formula I according to the
invention may for example have EC50 values below 1000 nM,
particularly below 200 nM, most preferably below 50 nM.
[0183] In view of their ability to inhibit the SGLT activity, the
compounds of general formula I according to the invention and the
corresponding pharmaceutically acceptable salts thereof are
theoretically suitable for the treatment and/or preventative
treatment of all those conditions or diseases which may be affected
by the inhibition of the SGLT activity, particularly the SGLT-2
activity. Therefore, compounds according to the invention are
particularly suitable for the prevention or treatment of diseases,
particularly metabolic disorders, or conditions such as type 1 and
type 2 diabetes mellitus, complications of diabetes (such as e.g.
retinopathy, nephropathy or neuropathies, diabetic foot, ulcers,
macroangiopathies), metabolic acidosis or ketosis, reactive
hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder,
insulin resistance, metabolic syndrome, dyslipidaemias of different
origins, atherosclerosis and related diseases, obesity, high blood
pressure, chronic heart failure, edema and hyperuricaemia. These
substances are also suitable for preventing beta-cell degeneration
such as e.g. apoptosis or necrosis of pancreatic beta cells. The
substances are also suitable for improving or restoring the
functionality of pancreatic cells, and also of increasing the
number and size of pancreatic beta cells. The compounds according
to the invention may also be used as diuretics or antihypertensives
and are suitable for the prevention and treatment of acute renal
failure.
[0184] In particular, the compounds according to the invention,
including the physiologically acceptable salts thereof, are
suitable for the prevention or treatment of diabetes, particularly
type 1 and type 2 diabetes mellitus, and/or diabetic
complications.
[0185] The dosage required to achieve the corresponding activity
for treatment or prevention usually depends on the compound which
is to be administered, the patient, the nature and gravity of the
illness or condition and the method and frequency of administration
and is for the patient's doctor to decide. Expediently, the dosage
may be from 1 to 100 mg, preferably 1 to 30 mg, by intravenous
route, and 1 to 1000 mg, preferably 1 to 100 mg, by oral route, in
each case administered 1 to 4 times a day. For this purpose, the
compounds of formula I prepared according to the invention may be
formulated, optionally together with other active substances,
together with one or more inert conventional carriers and/or
diluents, e.g. with corn starch, lactose, glucose, microcrystalline
cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid,
tartaric acid, water, water/ethanol, water/glycerol,
water/sorbitol, water/polyethylene glycol, propylene glycol,
cetylstearyl alcohol, carboxymethylcellulose or fatty substances
such as hard fat or suitable mixtures thereof, to produce
conventional galenic preparations such as plain or coated tablets,
capsules, powders, suspensions or suppositories.
[0186] The compounds according to the invention may also be used in
conjunction with other active substances, particularly for the
treatment and/or prevention of the diseases and conditions
mentioned above. Other active substances which are suitable for
such combinations include for example those which potentiate the
therapeutic effect of an SGLT antagonist according to the invention
with respect to one of the indications mentioned and/or which allow
the dosage of an SGLT antagonist according to the invention to be
reduced. Therapeutic agents which are suitable for such a
combination include, for example, antidiabetic agents such as
metformin, sulphonylureas (e.g. glibenclamide, tolbutamide,
glimepiride), nateglinide, repaglinide, thiazolidinediones (e.g.
rosiglitazone, pioglitazone), PPAR-gamma-agonists (e.g. GI 262570)
and antagonists, PPAR-gamma/alpha modulators (e.g. KRP 297),
alpha-glucosidase inhibitors (e.g. acarbose, voglibose), DPPIV
inhibitors (e.g. LAF237, MK-431), alpha2-antagonists, insulin and
insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or
amylin. The list also includes inhibitors of protein
tyrosinephosphatase 1, substances that affect deregulated glucose
production in the liver, such as e.g. inhibitors of
glucose-6-phosphatase, or fructose-1,6-bisphosphatase, glycogen
phosphorylase, glucagon receptor antagonists and inhibitors of
phosphoenol pyruvate carboxykinase, glycogen synthase kinase or
pyruvate dehydrokinase, lipid lowering agents such as for example
HMG-CoA-reductase inhibitors (e.g. simvastatin, atorvastatin),
fibrates (e.g. bezafibrate, fenofibrate), nicotinic acid and the
derivatives thereof, PPAR-alpha agonists, PPAR-delta agonists, ACAT
inhibitors (e.g. avasimibe) or cholesterol absorption inhibitors
such as, for example, ezetimibe, bile acid-binding substances such
as, for example, cholestyramine, inhibitors of ileac bile acid
transport, HDL-raising compounds such as CETP inhibitors or ABC1
regulators or active substances for treating obesity, such as
sibutramine or tetrahydrolipostatin, dexfenfluramine, axokine,
antagonists of the cannabinoid1 receptor, MCH-1 receptor
antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists or
.beta.3-agonists such as SB-418790 or AD-9677 and agonists of the
5HT2c receptor.
[0187] Moreover, combinations with drugs for influencing high blood
pressure, chronic heart failure or atherosclerosis such as e.g.
A-II antagonists or ACE inhibitors, ECE inhibitors, diuretics,
.beta.-blockers, Ca-antagonists, centrally acting
antihypertensives, antagonists of the alpha-2-adrenergic receptor,
inhibitors of neutral endopeptidase, thrombocyte aggregation
inhibitors and others or combinations thereof are suitable.
Examples of angiotensin II receptor antagonists are candesartan
cilexetil, potassium losartan, eprosartan mesylate, valsartan,
telmisartan, irbesartan, EXP-3174, L-158809, EXP-3312, olmesartan,
medoxomil, tasosartan, KT-3-671, GA-0113, RU-64276, EMD-90423,
BR-9701, etc. Angiotensin II receptor antagonists are preferably
used for the treatment or prevention of high blood pressure and
complications of diabetes, often combined with a diuretic such as
hydrochlorothiazide.
[0188] A combination with uric acid synthesis inhibitors or
uricosurics is suitable for the treatment or prevention of
gout.
[0189] A combination with GABA-receptor antagonists, Na-channel
blockers, topiramat, protein-kinase C inhibitors, advanced
glycation end product inhibitors or aldose reductase inhibitors may
be used for the treatment or prevention of complications of
diabetes.
[0190] The dosage for the combination partners mentioned above is
usefully 1/5 of the lowest dose normally recommended up to 1/1 of
the normally recommended dose. Therefore, in another aspect, this
invention relates to the use of a compound according to the
invention or a physiologically acceptable salt of such a compound
combined with at least one of the active substances described above
as a combination partner, for preparing a pharmaceutical
composition which is suitable for the treatment or prevention of
diseases or conditions which can be affected by inhibiting the
sodium-dependent glucose cotransporter SGLT. These are preferably
metabolic diseases, particularly one of the diseases or conditions
listed above, most particularly diabetes or diabetic
complications.
[0191] The use of the compound according to the invention, or a
physiologically acceptable salt thereof, in combination with
another active substance may take place simultaneously or at
staggered times, but particularly within a short space of time. If
they are administered simultaneously, the two active substances are
given to the patient together; while if they are used at staggered
times the two active substances are given to the patient within a
period of less than or equal to 12 hours, but particularly less
than or equal to 6 hours.
[0192] Consequently, in another aspect, this invention relates to a
pharmaceutical composition which comprises a compound according to
the invention or a physiologically acceptable salt of such a
compound and at least one of the active substances described above
as combination partners, optionally together with one or more inert
carriers and/or diluents.
[0193] Thus, for example, a pharmaceutical composition according to
the invention comprises a combination of a compound of formula I
according to the invention or a physiologically acceptable salt of
such a compound and at least one angiotensin II receptor antagonist
optionally together with one or more inert carriers and/or
diluents.
[0194] The compound according to the invention, or a
physiologically acceptable salt thereof, and the additional active
substance to be combined therewith may both be present together in
one formulation, for example a tablet or capsule, or separately in
two identical or different formulations, for example as a so-called
kit-of-parts.
[0195] In the foregoing and following text, H atoms of hydroxyl
groups are not explicitly shown in every case in structural
formulae. The Examples that follow are intended to illustrate the
present invention without restricting it:
Preparation of the Starting Compounds:
EXAMPLE I
##STR00020##
[0196] (5-bromo-2-chloro-phenyl)-(4-methoxy-phenyl)-methanone
[0197] 38.3 ml oxalyl chloride and 0.8 ml of dimethylformamide are
added to a mixture of 100 g of 5-bromo-2-chloro-benzoic acid in 500
ml dichloromethane. The reaction mixture is stirred for 14 h, then
filtered and separated from all volatile constituents in the rotary
evaporator. The residue is dissolved in 150 ml dichloromethane, the
solution is cooled to -5.degree. C., and 46.5 g of anisole are
added. Then 51.5 g of aluminium trichloride are added batchwise so
that the temperature does not exceed 5.degree. C. The solution is
stirred for another 1 h at 1-5.degree. C. and then poured onto ice.
The organic phase is separated off and the aqueous phase is
extracted another three times with dichloromethane. The combined
organic phases are washed with aqueous 1 M hydrochloric acid, twice
with 1 M sodium hydroxide solution and with saturated sodium
chloride solution. Then the organic phase is dried, the solvent is
removed and the residue is recrystallised in ethanol.
[0198] Yield: 86.3 g (64% of theory)
[0199] Mass spectrum (ESI.sup.+): m/z=325/327/329 (Br+Cl)
[M+H].sup.+
[0200] The following compounds are obtained analogously to Example
I:
(1) (5-bromo-2-iodo-phenyl)-(4-ethoxy-phenyl)-methanone
##STR00021##
[0202] Mass spectrum (ESI.sup.+): m/z=431/433 (Br) [M+H].sup.+
(2) (5-bromo-2-chloro-phenyl)-(4-iodo-phenyl)-methanone
##STR00022##
[0203] EXAMPLE II
##STR00023##
[0204] 4-bromo-1-chloro-2-(4-methoxy-benzyl)-benzene
[0205] A solution of 86.2 g
(5-bromo-2-chloro-phenyl)-(4-methoxy-phenyl)-methanone and 101.5 ml
triethylsilane in 75 ml dichloromethane and 150 ml acetonitrile is
cooled to 10.degree. C. Then with stirring 50.8 ml of boron
trifluoride etherate are added so that the temperature does not
exceed 20.degree. C. The solution is stirred for 14 h at ambient
temperature, before another 9 ml triethylsilane and 4.4 ml boron
trifluoride etherate are added. The solution is stirred for a
further 3 h at 45-50.degree. C. and then cooled to ambient
temperature. A solution of 28 g potassium hydroxide in 70 ml of
water is added and the mixture is stirred for 2 h. Then the organic
phase is separated off and the aqueous phase is extracted another
three times with diisopropylether. The combined organic phases are
washed twice with 2 M potassium hydroxide solution and once with
aqueous sodium chloride solution and then dried over sodium
sulphate. After the solvent has been eliminated the residue is
stirred in ethanol, separated off again and dried at 60.degree.
C.
[0206] Yield: 50.0 g (61% of theory)
[0207] Mass spectrum (ESI.sup.+): m/z=310/312/314 (Br+Cl)
[M+H].sup.+
[0208] The following compounds are obtained analogously to Example
II:
(1) 4-bromo-1-iodo-2-(4-ethoxy-benzyl)-benzene
##STR00024##
[0210] Mass spectrum (ESI.sup.+): m/z=434/436
[M+NH.sub.4].sup.+
(2) 4-bromo-1-chloro-2-(4-iodo-benzyl)-benzene
##STR00025##
[0211] EXAMPLE III
##STR00026##
[0212] 4-(5-bromo-2-chloro-benzyl)-phenol
[0213] A solution of 14.8 g
4-bromo-1-chloro-2-(4-methoxy-benzyl)-benzene in 150 ml
dichloromethane is cooled in the ice bath. Then 50 ml of a 1 M
solution of boron tribromide in dichloromethane are added, and the
solution is stirred for 2 h at ambient temperature. The solution is
then cooled in the ice bath again, and saturated potassium
carbonate solution is added dropwise. At ambient temperature the
mixture is adjusted with aqueous 1 M hydrochloric acid to a pH of
1, the organic phase is separated off and the aqueous phase is
extracted another three times with ethyl acetate. The combined
organic phases are dried over sodium sulphate, and the solvent is
removed completely.
[0214] Yield: 13.9 g (98% of theory)
[0215] Mass spectrum (ESI.sup.-): m/z=295/297/299 (Br+Cl)
[M-H].sup.-
EXAMPLE IV
##STR00027##
[0216]
[4-(5-bromo-2-chloro-benzyl)-phenoxy]-tert-butyl-dimethyl-silane
[0217] A solution of 13.9 g 4-(5-bromo-2-chloro-benzyl)-phenol in
140 ml dichloromethane is cooled in the ice bath. Then 7.54 g
tert-butyldimethylsilylchlorid in 20 ml dichloromethane are added
followed by 9.8 ml triethylamine and 0.5 g dimethylaminopyridine.
The solution is stirred for 16 h at ambient temperature and then
diluted with 100 ml dichloromethane. The organic phase is washed
twice with aqueous 1 M hydrochloric acid and once with aqueous
sodium hydrogen carbonate solution and then dried over sodium
sulphate. After the solvent has been eliminated the residue is
filtered through silica gel (cyclohexane/ethyl acetate 100:1).
[0218] Yield: 16.8 g (87% of theory)
[0219] Mass spectrum (EI): m/z=410/412/414 (Br+Cl) [M].sup.+
EXAMPLE V
##STR00028##
[0220] 1-bromo-4-triisopropylsilylethynyl-benzene
[0221] Under argon 11.6 ml triisopropylacetylen and 14.4 ml
triethylamine followed by 0.2 g copper iodide and 0.73 g
bis-(triphenylphosphine)-palladium dichloride are added to an
oxygen-free solution of 15.0 g 1-bromo-4-iodo-benzene in 150 ml dry
tetrahydrofuran. The solution is stirred for 16 h at ambient
temperature and then filtered through Celite and evaporated down.
The residue is chromatographed through silica gel
(cyclohexane).
[0222] Yield: 17.4 g (100% of theory)
[0223] Mass spectrum (ESI.sup.+): m/z=336/338 (Br) [M].sup.+
[0224] The following compounds are obtained analogously to Example
V:
(1)
4-bromo-1-(triisopropylsilylethynyl)-2-(4-ethoxy-benzyl)-benzene
[0225] 4-bromo-1-iodo-2-(4-ethoxy-benzyl)-benzene is used as the
starting material for the coupling reaction described
hereinbefore.
##STR00029##
[0226] Mass spectrum (ESI.sup.+): m/z=471/473 (Br) [M+H].sup.+
(2)
[4-(5-bromo-2-chloro-benzyl)-phenylethynyl]-triisopropyl-silane
[0227] 4-bromo-1-chloro-2-(4-iodo-benzyl)-benzene is used as
starting material.
##STR00030##
[0228] This compound may also be obtained according to Example
X.
EXAMPLE VI
##STR00031##
[0229]
(5-bromo-2-fluoro-phenyl)-[4-[(triisopropylsilyl)-ethynyl]-phenyl]--
methanol
[0230] 33.8 ml of a 1.6 M solution of n-butyllithium in hexane are
added dropwise under argon to a solution of 17.4 g
1-bromo-4-triisopropylsilylethynyl-benzene in 120 ml dry
tetrahydrofuran chilled to -78.degree. C. The solution is stirred
for 1 h at -70.degree. C. Then 10.8 g 5-bromo-2-fluoro-benzaldehyde
dissolved in 30 ml of tetrahydrofuran are added dropwise over 15
min. The resulting solution is left in the cooling bath to warm up
overnight to ambient temperature. Then water is added and the
mixture is extracted with ethyl acetate. The combined organic phase
are dried over sodium sulphate, and the solvent is removed. The
residue is purified through silica gel (cyclohexane/ethyl acetate
4:1).
[0231] Yield: 14.3 g (60% of theory)
[0232] Mass spectrum (ESI.sup.+): m/z=461/463 (Br) [M+H].sup.+
[0233] The following compounds are obtained analogously to Example
VI:
(1)
(3-bromo-phenyl)-{4-[(triisopropylsilyl)-ethynyl]-phenyl}-methanol
##STR00032##
[0235] Mass spectrum (ESI.sup.-): m/z=487/489 (Br)
[M+HCOO].sup.-
(2)
(5-bromo-2-methoxy-phenyl)-{4-[(triisopropylsilyl)-ethynyl]-phenyl}-me-
thanol
##STR00033##
[0237] Mass spectrum (ESI.sup.+): m/z=473/475 (Br) [M+H].sup.+
EXAMPLE VII
##STR00034##
[0238]
[4-(5-bromo-2-fluoro-benzyl)-phenylethynyl]-triisopropyl-silane
[0239] A solution of 5.6 g
(5-bromo-2-fluoro-phenyl)-{4-[(triisopropylsilyl)-ethynyl]-phenyl}-methan-
ol and 4.1 ml triethylsilane in 50 ml dichloromethane is cooled in
the ice bath. Then 4.7 ml trifluoroacetic acid are slowly added
dropwise, and the solution is stirred for 4 h at ambient
temperature. The solution is diluted with dichloromethane and
washed with aqueous sodium hydrogen carbonate solution. After
drying over sodium sulphate the solvent is removed and the residue
is purified using silica gel (cyclohexane).
[0240] Yield: 2.6 g (48% of theory)
[0241] Mass spectrum (EI): m/z=445/447 (Br) [M].sup.+
[0242] The following compounds are obtained analogously to Example
VII:
(1) [4-(3-bromo-benzyl)-phenylethynyl]-triisopropyl-silane
##STR00035##
[0244] Mass spectrum (ESI.sup.+): m/z=427/429 (Br) [M+H].sup.+
(2)
[4-(5-bromo-2-methoxy-benzyl)-phenylethynyl]-triisopropyl-silane
[0245] In a departure from the process described hereinbefore the
reaction solution is stirred in the ice bath instead of at ambient
temperature until the reaction is complete.
##STR00036##
[0246] Mass spectrum (ESI.sup.+): m/z=457/459 (Br) [M+H].sup.+
EXAMPLE VIII
##STR00037##
[0247] 4-bromo-2-brommethyl-1-chloro-benzene
[0248] 4.0 g N-bromosuccinimide are slowly added to a solution of
5.0 g of 4-bromo-1-chloro-2-hydroxymethyl-benzene and 5.9 g
triphenylphosphine in 50 ml of tetrahydrofuran chilled to 5.degree.
C. After 1 h stirring at ambient temperature the precipitate is
filtered off and the solvent is eliminated in vacuo. The residue is
purified through silica gel (cyclohexane/ethyl acetate 50:1).
[0249] Yield: 4.9 g (76% of theory)
[0250] Mass spectrum (EI): m/z=282/284/286 (Br+Cl) [M].sup.+
EXAMPLE IX
##STR00038##
[0251] (4-iodo-phenylethynyl)-triisopropyl-silane
[0252] Under argon 18.0 g sodium iodide (dry), 0.6 g copper iodide
and 0.8 g N,N'-dimethyl-cyclohexane-1,2-diamine are added to a
solution of 20.0 g (4-bromo-phenylethynyl)-triisopropyl-silane. The
solution is refluxed with stirring for 24 h and then cooled to
ambient temperature. 1% ammonia solution (100 ml) is added and the
mixture is extracted with ethyl acetate. After drying over sodium
sulphate the solvent is removed and the residue is purified using
silica gel (cyclohexane).
[0253] Yield: 21.0 g (92% of theory)
[0254] Mass spectrum (EI): m/z=384 [M].sup.+
EXAMPLE X
##STR00039##
[0255]
[4-(5-bromo-2-chloro-benzyl)-phenylethynyl]-triisopropyl-silane
[0256] Under argon 0.66 ml of a 2 M solution of isopropylmagnesium
chloride in tetrahydrofuran are added dropwise to a solution of
0.50 g (4-iodo-phenylethynyl)-triisopropyl-silane in 2.2 ml dry
tetrahydrofuran chilled to -25.degree. C. The solution is stirred
for 30 min at -25.degree. C. and then combined with 0.26 ml of a 1
M solution of CuCN*2 LiCl in tetrahydrofuran (prepared by
dissolving CuCN and LiCl in the ratio 1:2). Shortly afterwards,
0.35 g 4-bromo-2-bromomethyl-1-chlorbenzene are added and the
reaction mixture is brought up to -5.degree. C. in the cooling
bath. After 6 h stirring at -5.degree. C. the solution is heated to
ambient temperature and stirred overnight. Then a mixture of
saturated ammonium chloride solution and 25% ammonia solution (9:1)
is added and the resulting mixture is added to water. The organic
phase is separated off and the aqueous phase is extracted with
ethyl acetate, the combined organic phases are dried over sodium
sulphate, and the solvent is removed. The residue is purified
through silica gel (cyclohexane).
[0257] Yield: 0.28 g (50% of theory)
[0258] Mass spectrum (EI): m/z=461/463/465 (Br+Cl) [M+H].sup.+
EXAMPLE XI
##STR00040##
[0259] 2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone
[0260] A solution of 20 g D-glucono-1,5-lactone and 98.5 ml
N-methylmorpholine in 200 ml of tetrahydrofuran is cooled to
-5.degree. C. Then 85 ml trimethylsilylchloride are added dropwise
so that the temperature does not exceed 5.degree. C. The solution
is then stirred for 1 h at ambient temperature, 5 h at 35.degree.
C. and again for 14 h at ambient temperature. After the addition of
300 ml of toluene the solution is cooled in the ice bath, and 500
ml of water are added so that the temperature does not exceed
10.degree. C. The organic phase is then separated off and washed in
each case once with aqueous sodium dihydrogen phosphate solution,
water and saturated aqueous sodium chloride solution. The solvent
is removed, the residue is taken up in 250 ml of toluene and the
solvent is again removed completely.
[0261] Yield: 52.5 g (approx. 90% pure)
[0262] Mass spectrum (ESI.sup.+): m/z=467 [M+H].sup.+
EXAMPLE XII
##STR00041##
[0263]
1-fluoro-4-(1-methoxy-D-glucopyranos-1-yl)-2-(4-triisopropylsilylet-
hynyl-benzyl)-benzene
[0264] A solution of 4.46 g
[4-(5-bromo-2-fluoro-benzyl)-phenylethynyl]-triisopropyl-silane in
30 ml dry diethyl ether is cooled to -80.degree. C. under argon.
11.8 ml of a 1.7 M solution of tert-butyllithium in pentane are
slowly added dropwise to the cooled solution, and then the solution
is stirred for 45 min at -80.degree. C. Then a solution of 5.19 g
of 2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone in 50 ml
diethyl ether, chilled to -80.degree. C., is added dropwise to this
solution through a transfer needle. The resulting solution is
stirred for 3 h at -78.degree. C. Then a solution of 1.7 ml
methanesulphonic acid in 50 ml of methanol is added, the cooling
bath is removed and the solution is stirred for 16 h at ambient
temperature. The solution is then neutralised with
ethyldiisopropylamine and evaporated down to dryness. The residue
is purified through silica gel (dichloromethane/methanol
50:1->4:1).
[0265] Yield: 2.8 g (50% of theory)
[0266] Mass spectrum (ESI.sup.+): m/z=576 [M+NH.sub.4].sup.+
[0267] The following compounds are obtained analogously to Example
XII:
(1)
1-methoxy-4-(1-methoxy-D-glucopyranos-1-yl)-2-(4-triisopropylsilylethy-
nyl-benzyl)-benzene
[0268] Advantageously the reaction mixture is mixed with only a
small excess of methanesulphonic acid.
##STR00042##
[0269] Mass spectrum (ESI.sup.+): m/z=588 [M+NH.sub.4].sup.+
(2)
1-chloro-4-(1-methoxy-D-glucopyranos-1-yl)-2-(4-triisopropylsilylethyn-
yl-benzyl)-benzene
##STR00043##
[0271] Mass spectrum (ESI.sup.+): m/z=592/594 (Cl)
[M+NH.sub.4].sup.+
EXAMPLE XIII
##STR00044##
[0272]
1-fluoro-4-(2,3,4,6-tetra-O-acetyl-.beta.-D-glucopyranos-1-yl)-2-(4-
-triisopropylsilylethynyl-benzyl)-benzene
[0273] A solution of 0.8 g
1-fluoro-4-(1-methoxy-D-glucopyranos-1-yl)-2-(4-triisopropylsilylethynyl--
benzyl)-benzene and 0.5 ml triethylsilane in 6 ml dichloromethane
and 10 ml acetonitrile is cooled to -10.degree. C. 0.27 ml boron
trifluoride etherate are added dropwise to the cooled solution. The
solution is then stirred for 3 h in the ice bath. Aqueous sodium
hydrogen carbonate solution is added to the solution and then the
mixture is extracted with ethyl acetate. The organic phase is dried
over sodium sulphate, the solvent is removed and the residue is
taken up in 6 ml dichloromethane. Then 1.2 ml of pyridine, 1.3 ml
of acetic anhydride and 8 mg of 4-dimethylaminopyridine are added.
The solution is stirred for 1 h at ambient temperature and then
combined with water. The mixture is extracted with dichloromethane,
the organic phase is washed with 1 M hydrochloric acid and dried
over sodium sulphate. After the solvent has been eliminated the
residue is chromatographed through silica gel (cyclohexane/ethyl
acetate 4:1->1:1).
[0274] Yield: 0.23 g (23% of theory)
[0275] Mass spectrum (ESI.sup.+): m/z=714 [M+NH.sub.4].sup.+
[0276] The following compounds are obtained analogously to Example
XIII:
(1)
1-methoxy-4-(2,3,4,6-tetra-O-acetyl-.beta.-D-glucopyranos-1-yl)-2-(4-t-
riisopropylsilylethynyl-benzyl)-benzene
##STR00045##
[0278] Mass spectrum (ESI.sup.+): m/z=726 [M+NH.sub.4].sup.+
(2)
1-chloro-4-(2,3,4,6-tetra-O-acetyl-.beta.-D-glucopyranos-1-yl)-2-(4-tr-
iisopropylsilylethynyl-benzyl)-benzene
##STR00046##
[0280] Mass spectrum (ESI.sup.+): m/z=730/732 (Cl)
[M+NH.sub.4].sup.+
EXAMPLE XIV
##STR00047##
[0281]
1-(2,3,4,6-Tetra-O-acetyl-1-methoxy-D-glucopyranos-1-yl)-3-(4-triis-
opropylsilylethynyl-benzyl)-benzene
[0282] A solution of 2.6 g
[4-(3-bromo-benzyl)-phenylethynyl]-triisopropyl-silane in 20 ml dry
diethyl ether is cooled to -80.degree. C. under argon. 7.9 ml of a
1.7 M solution of tert-butyllithium in pentane are slowly added
dropwise to the cooled solution, and then the solution is stirred
for 30 min at -80.degree. C. A solution of 3.2 g
2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone in 30 ml
diethyl ether chilled to -80.degree. C. is then added dropwise to
this solution through a transfer needle. The resulting solution is
stirred for 2 h at -78.degree. C. and then another solution of 1.0
g 2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone in 10 ml
diethyl ether chilled to -80.degree. C. is added dropwise. After
another hour's stirring at -78.degree. C. a solution of 2 ml
methanesulphonic acid in 20 ml of methanol is added, the cooling
bath is removed and the solution is stirred for 16 h at ambient
temperature. The solution is then neutralised with
ethyldiisopropylamine, the solvent is removed completely and the
residue is taken up in 50 ml of toluene. 8.5 ml
ethyldiisopropylamine are added, and the solution is cooled in the
ice bath. Then 4.3 ml acetic anhydride and 0.15 g
4-dimethylaminopyridine are added. The solution is stirred for 2 h
at ambient temperature and then combined with aqueous sodium
hydrogen carbonate solution. It is extracted with ethyl acetate,
the organic phases are dried over sodium sulphate, and the solvent
is removed. The residue is chromatographed through silica gel
(cyclohexane/ethyl acetate 4:1->1:3).
[0283] Yield: 2.0 g (46% of theory)
[0284] Mass spectrum (ESI.sup.+): m/z=726 [M+NH.sub.4].sup.+
[0285] The following compound is obtained analogously to Example
XIV:
(1)
1-(triisopropylsilylethynyl)-4-(2,3,4,6-tetra-O-acetyl-1-methoxy-D-glu-
copyranos-1-yl)-2-(4-ethoxy-benzyl)-benzene
##STR00048##
[0287] Mass spectrum (ESI.sup.+): m/z=770 [M+NH.sub.4].sup.+
EXAMPLE XV
##STR00049##
[0288]
1-(2,3,4,6-Tetra-O-acetyl-.beta.-D-glucopyranos-1-yl)-3-(4-triisopr-
opylsilylethynyl-benzyl)-benzene
[0289] 1.2 ml triethylsilane and 0.36 ml boron trifluoride etherate
are added dropwise to an ice-cooled solution of 1.0 g
1-(2,3,4,6-tetra-O-acetyl-1-methoxy-D-glucopyranos-1-yl)-3-(4-triisopropy-
lsilylethynyl-benzyl)-benzene and 25 .mu.l water in 10 ml
acetonitrile. The solution is then stirred for 3 h in the ice bath
and for 1 h at ambient temperature. Then the solution is again
cooled in the ice bath, and another 1.2 ml triethylsilane and 0.36
ml boron trifluoride etherate are added. The solution is stirred
for a further 0.5 h in the ice bath and 2 h at ambient temperature.
Aqueous sodium hydrogen carbonate solution is then added to the
solution, and the resulting solution is extracted with ethyl
acetate. The organic phase is dried over sodium sulphate and the
solvent is removed.
[0290] Yield: 0.78 g (81% of theory)
[0291] Mass spectrum (ESI.sup.+): m/z=696 [M+NH.sub.4].sup.+
[0292] The following compound is obtained analogously to Example
XV:
(1)
1-(triisopropylsilylethynyl)-4-(2,3,4,6-tetra-O-acetyl-.beta.-D-glucop-
yranos-1-yl)-2-(4-ethoxy-benzyl)-benzene
##STR00050##
[0293] EXAMPLE XVI
##STR00051##
[0294]
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-hydroxybenzyl)-benzene
[0295] A solution of 4.0 g
[4-(5-bromo-2-chloro-benzyl)-phenoxy]-tert-butyl-dimethyl-silane in
42 ml dry diethyl ether is cooled to -80.degree. C. under argon.
11.6 ml of a 1.7 M solution of tert-butyllithium in pentane are
slowly added dropwise to the cooled solution, and then the solution
is stirred for 30 min at -80.degree. C. This solution is then added
dropwise through a transfer needle, which is cooled with dry ice,
to a solution of 4.78 g
2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone in 38 ml
diethyl ether chilled to -80.degree. C. The resulting solution is
stirred for 3 h at -78.degree. C. Then a solution of 1.1 ml
methanesulphonic acid in 35 ml of methanol is added and the
solution is stirred for 16 h at ambient temperature. The solution
is then neutralised with solid sodium hydrogen carbonate, ethyl
acetate is added and the methanol is removed together with the
ether. Aqueous sodium hydrogen carbonate solution is added to the
remaining solution and extracted four times with ethyl acetate. The
organic phases are dried over sodium sulphate and evaporated down.
The residue is dissolved in 30 ml acetonitrile and 30 ml
dichloromethane and the solution is cooled to -10.degree. C. After
the addition of 4.4 ml triethylsilane 2.6 ml boron trifluoride
etherate are added dropwise so that the temperature does not exceed
-5.degree. C. After the addition has ended the solution is stirred
for another 5 h at -5 to -10.degree. C. and then quenched by the
addition of aqueous sodium hydrogen carbonate solution. The organic
phase is separated off and the aqueous phase is extracted four
times with ethyl acetate. The combined organic phase are dried over
sodium sulphate, the solvent is removed and the residue is purified
using silica gel. The product then obtained is an approx. 6:1
mixture of .beta./.alpha. which can be converted into the pure
.beta.-anomer by total acetylation of the hydroxy groups with
acetic anhydride and pyridine in dichloromethane and
recrystallising the product in ethanol. The product thus obtained
is converted into the title compound by reacting in methanol with 4
M potassium hydroxide solution.
[0296] Yield: 1.6 g (46% of theory)
[0297] Mass spectrum (ESI.sup.+): m/z=398/400 (Cl) [M+H].sup.+
EXAMPLE XVII
##STR00052##
[0298]
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulpho-
nyloxy)-benzyl]-benzene
[0299] 10 mg 4-dimethylaminopyridine are added to a solution of
0.38 g
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-hydroxybenzyl)-benzene,
0.21 ml triethylamine and 0.39 g
N,N-bis-(trifluoromethanesulphonyl)-aniline in 10 ml dry
dichloromethane. The solution is stirred for 4 h at ambient
temperature and then combined with aqueous sodium chloride
solution. It is extracted with ethyl acetate, the organic extracts
are dried over sodium sulphate, and the solvent is removed. The
residue is chromatographed through silica gel
(dichloromethane/methanol 1:0->4:1).
[0300] Yield: 0.33 g (64% of theory)
[0301] Mass spectrum (ESI.sup.+): m/z=530/532 (Cl)
[M+NH.sub.4].sup.+
EXAMPLE XVIII
##STR00053##
[0302] 2,3,4,6-Tetra-O-benzyl-D-glucopyranone
[0303] 4 g freshly activated molecular sieve 4 .ANG. and 3.3 g
N-methylmorpholine-N-oxide are added to a solution of 10.0 g
2,3,4,6-tetra-O-benzyl-.alpha.-D-glucopyranose in 140 ml
dichloromethane. The solution is stirred for 20 min at ambient
temperature, before adding 0.3 g of tetrapropylammonium
perruthenate. After 2 h stirring at ambient temperature the
solution is diluted with dichloromethane and filtered through
Celite. The filtrate is washed with aqueous sodium thiosulphate
solution and water and then dried over sodium sulphate. After the
solvent has been eliminated the residue is chromatographed through
silica gel (cyclohexane/ethyl acetate 4:1).
[0304] Yield: 8.2 g (82% of theory)
[0305] Mass spectrum (ESI.sup.+): m/z=539 [M+H].sup.+
EXAMPLE XIX
##STR00054##
[0306]
1-(2,3,4,6-Tetra-O-benzyl-1-hydroxy-D-glucopyranos-1-yl)-3-[4-(tert-
-butyl-dimethyl-silyloxy)-benzyl]-4-methyl-benzene
[0307] A solution of 0.34 g
[4-(5-bromo-2-methyl-benzyl)-phenoxy]-tert-butyl-dimethyl-silane in
3 ml dry tetrahydrofuran is cooled to -80.degree. C. under argon.
0.54 ml of a 1.6 M solution of n-butyllithium in hexane are added
dropwise to the cooled solution, and the solution is stirred for
1.5 h at -78.degree. C. A solution of 0.43 g
2,3,4,6-tetra-O-benzyl-D-glucopyranone in 2.5 ml of tetrahydrofuran
chilled to -80.degree. C. is added dropwise to this solution by
means of transfer needle. The resulting solution is stirred for 5 h
at -78.degree. C. The reaction is quenched with a solution of 0.1
ml acetic acid in 1 ml of tetrahydrofuran and heated to ambient
temperature. Then aqueous sodium hydrogen carbonate solution is
added and the mixture is extracted four times with ethyl acetate.
The organic phases are dried over sodium sulphate and evaporated
down. The residue is purified by chromatography on silica gel
(cyclohexane/ethyl acetate 15:1->4:1).
[0308] Yield: 0.48 g (approx. 88% pure)
[0309] Mass spectrum (ESI.sup.+): m/z=868 [M+H].sup.+
EXAMPLE XX
##STR00055##
[0310]
1-(2,3,4,6-tetra-O-benzyl-.beta.-D-glucopyranos-1-yl)-3-(4-hydroxy--
benzyl)-4-methyl-benzene
[0311] A solution of 0.48 g (approx. 88% pure)
1-(2,3,4,6-tetra-O-benzyl-1-hydroxy-D-glucopyranosyl)-3-[4-(tert-butyl-di-
methyl-silyloxy)-benzyl]-4-methyl-benzene in 3.5 ml dry
acetonitrile is cooled to -40.degree. C. under argon. 0.13 ml
triisopropylsilane and 0.08 ml boron trifluoride etherate are added
dropwise to the cooled solution. The solution is stirred for 3 h at
-35.degree. C., before another 0.02 ml of triisopropylsilane and
0.01 ml of boron trifluoride etherate are added. After a further 2
h at -40.degree. C. aqueous potassium carbonate is added and the
solution is stirred for 1 h at ambient temperature. Then it is
diluted with water and extracted four times with ethyl acetate. The
organic phase is dried over sodium sulphate, concentrated and
chromatographed through silica gel (cyclohexane/ethyl acetate
10:1->4:1).
[0312] Yield: 0.24 g (68% of theory). Mass spectrum (ESI.sup.+):
m/z=738 [M+NH.sub.4].sup.+
EXAMPLE XXI
##STR00056##
[0313]
1-(2,3,4,6-tetra-O-benzyl-.beta.-D-glucopyranos-1-yl)-3-[4-(tetrahy-
drofuran-3-yloxy)-benzyl]-4-methyl-benzene
[0314] 0.10 g tetrahydrofuran-3-yl toluene-4-sulphonate are added
to a mixture of 0.24 g
1-(2,3,4,6-tetra-O-benzyl-.beta.-D-glucopyranos-1-yl)-3-(4-hydroxy-benzyl-
)-4-methyl-benzene and 0.13 g caesium carbonate in 2.5 ml of
dimethylformamide. The mixture is stirred for 4 h at 65.degree. C.,
before water is added. It is extracted three times with ethyl
acetate, the organic phase is dried over sodium sulphate and the
solvent is removed. The residue is purified through silica gel
purified (cyclohexane/ethyl acetate 10:1->4:1).
[0315] Yield: 0.23 g (78% of theory). Mass spectrum (ESI.sup.+):
m/z=808 [M+H].sup.+
EXAMPLE XXII
##STR00057##
[0316]
1-(2,3,4,6-tetra-O-benzyl-.beta.-D-glucopyranos-1-yl)-3-[4-(trifluo-
romethylsulphonyloxy)-benzyl]-4-methyl-benzene
[0317] A solution of 0.62 g
1-(2,3,4,6-tetra-O-benzyl-.beta.-D-glucopyranos-1-yl)-3-(4-hydroxy-benzyl-
)-4-methyl-benzene in 4.5 ml dry dichloromethane is cooled to
-10.degree. C. under argon. 0.14 ml of pyridine and a solution of
0.3 g trifluoromethanesulphonic anhydride in 0.5 ml dichloromethane
are added to the cooled solution. The solution is stirred for 0.5 h
at -5 to -10.degree. C., before aqueous sodium hydrogen carbonate
solution is added. The mixture is extracted three times with
dichloromethane, the combined organic phases are washed with
aqueous 1 M hydrochloric acid and dried over sodium sulphate. After
the solvent has been eliminated the residue is chromatographed
through silica gel (cyclohexane/ethyl acetate 15:1->7:1).
[0318] Yield: 0.62 g (84% of theory)
[0319] Mass spectrum (ESI.sup.+): m/z=853 [M+H].sup.+
EXAMPLE XXIII
##STR00058##
[0320]
1-(2,3,4,6-tetra-O-benzyl-.beta.-D-glucopyranos-1-yl)-3-[4-(trimeth-
ylsilylethynyl)-benzyl]-4-methyl-benzene
[0321] Under argon, 27 mg copper iodide, 49 mg
bis-(triphenylphosphine)-palladium dichloride, 0.30 ml
triethylamine and finally 0.14 ml of trimethylsilylacetylene are
added to a solution of 0.60 g
1-(2,3,4,6-tetra-O-benzyl-.beta.-D-glucopyranos-1-yl)-3-[4-(triflu-
oromethylsulphonyloxy)-benzyl]-4-methyl-benzene in 3 ml of
dimethylformamide. The flask is tightly sealed and stirred for 4 h
at 90.degree. C. Then another 20 mg of
bis-(triphenylphosphine)-palladium dichloride and 0.6 ml
trimethylsilylacetylene are added, and the solution is stirred for
a further 4 h at 90.degree. C. Then aqueous sodium hydrogen
carbonate solution is added, the mixture is extracted three times
with ethyl acetate, and the combined organic phases are dried over
sodium sulphate. After the solvent has been eliminated the residue
is chromatographed through silica gel (cyclohexane/ethyl acetate
40:1->10:1).
[0322] Yield: 0.45 g (80% of theory)
[0323] Mass spectrum (ESI.sup.+): m/z=818 [M+NH.sub.4].sup.+
Preparation of the End Compounds:
EXAMPLE 1
##STR00059##
[0324]
1-chloro-2-(4-cyclopentyloxybenzyl)-4-(.beta.-D-glucopyranos-1-yl)--
benzene
[0325] 0.16 ml iodocyclopentane are added to a mixture of 0.25 g
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-hydroxybenzyl)-benzene
and 0.4 g caesium carbonate in 2.5 ml of dimethylformamide. The
mixture is stirred for 4 h at 45.degree. C., before another 0.1 g
caesium carbonate and 0.05 ml iodocyclopentane are added. After
another 14 h stirring at 45.degree. C. aqueous sodium chloride
solution is added and the mixture is extracted with ethyl acetate.
The organic phase is dried over sodium sulphate, the solvent is
removed and the residue is purified using silica gel
(dichloromethane/methanol 1:0->5:1).
[0326] Yield: 0.23 g (78% of theory)
[0327] Mass spectrum (ESI.sup.+): m/z=466/468 (Cl)
[M+NH.sub.4].sup.+
[0328] The following compounds are obtained analogously to Example
1:
(2)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yl-
oxy)-benzyl]-benzene
[0329] The reaction is carried out with
tetrahydrofuran-3-yl(S)-toluene-4-sulphonate as the coupling
partner.
##STR00060##
[0330] Mass spectrum (ESI.sup.+): m/z=451/453 (Cl) [M+H].sup.+
(3)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yl-
oxy)-benzyl]-benzene
[0331] The reaction is carried out with
tetrahydrofuran-3-yl(R)-toluene-4-sulphonate as the coupling
partner.
##STR00061##
[0332] Mass spectrum (ESI.sup.+): m/z=451/453 (Cl) [M+H].sup.+
(4)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(tetrahydrofuran-2-on-3-y-
loxy)-benzyl]-benzene
[0333] The reaction is carried out with 3-bromobutyrolactone as the
coupling partner.
##STR00062##
[0334] Mass spectrum (ESI.sup.+): m/z=465/467 (Cl) [M+H].sup.+
(5)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-cyclobutyloxy-benzyl)-ben-
zene
##STR00063##
[0336] Mass spectrum (ESI.sup.+): m/z=452/454 (Cl)
[M+NH.sub.4].sup.+
(6)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-cyclohexyloxy-benzyl)-ben-
zene
##STR00064##
[0338] Mass spectrum (ESI.sup.+): m/z=480/482 (Cl)
[M+NH.sub.4].sup.+
(7)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(tetrahydropyran-4-yloxy)-
-benzyl]-benzene
##STR00065##
[0340] Mass spectrum (ESI.sup.+): m/z=487/489 (Cl) [M+Na].sup.+
(8)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(1-acetyl-piperidin-4-ylo-
xy)-benzyl]-benzene
[0341] The reaction is carried out with
1-acetyl-4-methylsulphonyloxy-piperidine as the electrophile.
##STR00066##
[0342] Mass spectrum (ESI.sup.+): m/z=506/508 (Cl) [M+H].sup.+ (9)
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(1-tert-butyloxycarbonylpipe-
ridin-4-yloxy)-benzyl]-benzene
[0343] The reaction is carried out with
1-tert-butyloxycarbonyl-4-methylsulphonyloxy-piperidine as the
electrophile.
##STR00067##
[0344] Mass spectrum (ESI.sup.+): m/z=586/588 (Cl) [M+Na].sup.+
EXAMPLE 10
##STR00068##
[0345]
1-(.beta.-D-glucopyranos-1-yl)-4-methyl-3-[4-(tetrahydrofuran-3-ylo-
xy)-benzyl]-benzene
[0346] A mixture of 0.21 g
1-(2,3,4,6-tetra-O-benzyl-.beta.-D-glucopyranos-1-yl)-3-[4-(tetrahydrofur-
an-3-ylox)-benzyl]-4-methyl-benzene and 0.1 g of 10% palladium
hydroxide on charcoal in 3 ml of ethyl acetate is shaken for 24 h
at ambient temperature under a hydrogen pressure of 1 atm. Then the
same amount of catalyst is added again and the mixture is shaken
for a further 24 h under a hydrogen atmosphere. Then the catalyst
is filtered off, the filtrate is evaporated down and the residue is
chromatographed through silica gel (dichloromethane/methanol
1:0->5:1).
[0347] Yield: 0.06 g (49% of theory)
[0348] Mass spectrum (ESI.sup.+): m/z=448 [M+NH.sub.4].sup.+
EXAMPLE 11
##STR00069##
[0349]
(.beta.-D-glucopyranos-1-yl)-4-methyl-3-[4-(2-trimethylsilyl-ethyl)-
-benzyl]-benzene
[0350] A mixture of 0.29 g
1-(2,3,4,6-tetra-O-benzyl-.beta.-D-glucopyranos-1-yl)-4-methyl-3-[4-(trim-
ethylsilylethynyl)-benzyl]-benzene and 0.25 g of 10% palladium
hydroxide on charcoal in 3 ml of ethyl acetate is shaken for 24 h
at ambient temperature under a hydrogen pressure of 1 atm. Then
another 0.2 g of catalyst are added and the solution is shaken for
a further 20 h under a hydrogen atmosphere. Then the catalyst is
filtered off, the filtrate is evaporated down and the residue is
chromatographed through silica gel (dichloromethane/methanol
1:0->5:1).
[0351] Yield: 0.08 g (51% of theory)
[0352] Mass spectrum (ESI.sup.+): m/z=462 [M+NH.sub.4].sup.+
EXAMPLE 12
##STR00070##
[0353]
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzen-
e
[0354] 25 mg of copper iodide, 44 mg of
bis-(triphenylphosphine)-palladium dichloride, 0.30 ml
triethylamine and finally 0.14 ml of trimethylsilylacetylene are
added under argon to a solution of 0.32 g
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulphonyloxy-
)-benzyl]-benzene in 3 ml of dimethylformamide. The flask is
tightly sealed and stirred for 8 h at 90.degree. C. Then another 25
mg of bis-(triphenylphosphine)-palladium dichloride and 0.1 ml
trimethylsilylacetylene are added, and the solution is stirred for
a further 10 h at 90.degree. C. Then aqueous sodium hydrogen
carbonate solution is added, the mixture is extracted three times
with ethyl acetate, and the combined organic phases are dried over
sodium sulphate. After the solvent has been eliminated the residue
is dissolved in 5 ml of methanol and combined with 0.12 g potassium
carbonate. The mixture is stirred for 1 h at ambient temperature
and then neutralised with 1 M hydrochloric acid. Then the methanol
is evaporated off, the residue is combined with aqueous sodium
chloride solution and extracted with ethyl acetate. The organic
extracts collected are dried over sodium sulphate, and the solvent
is removed. The residue is chromatographed through silica gel
(dichloromethane/methanol 1:0->5:1).
[0355] Yield: 0.095 g (40% of theory)
[0356] Mass spectrum (ESI.sup.+): m/z=406/408 (Cl)
[M+NH.sub.4].sup.+
[0357] This compound may also be obtained according to Example
14.
EXAMPLE 13
##STR00071##
[0358]
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(piperidin-4-yloxy)-be-
nzyl]-benzene
[0359] 2 ml trifluoroacetic acid are added to a solution of 0.19 g
1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(1-tert-butlyoxycarbonylpipe-
ridin-4-yloxy)-benzyl]-benzene in 4 ml dichloromethane. The
solution is stirred for 1.5 h at ambient temperature and then
diluted with ethyl acetate and made basic with aqueous potassium
carbonate solution. The organic phase is separated off and the
aqueous phase is extracted with ethyl acetate. The combined organic
phases are dried over sodium sulphate and the solvent is eliminated
entirely.
[0360] Yield: 0.060 g (38% of theory)
[0361] Mass spectrum (ESI.sup.+): m/z=464/466 (Cl) [M+H].sup.+
EXAMPLE 14
##STR00072##
[0362]
1-fluoro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzen-
e
[0363] 0.33 ml of a 1 M solution of tetrabutylammoniumfluorid in
tetrahydrofuran are added to a solution of 0.23 g
1-fluoro-4-(2,3,4,6-tetra-O-acetyl-.beta.-D-glucopyranos-1-yl)-2-(triisop-
ropylsilylethynyl-benzyl)-benzene in 1.5 ml of tetrahydrofuran. The
solution is stirred for 1 h at ambient temperature. Then 1 ml of
methanol and 1.5 ml of 4 M potassium hydroxide solution are added
and the solution is stirred for a further hour at ambient
temperature. The solution is neutralised with 1 M hydrochloric acid
and then the methanol is evaporated off. The residue is combined
with aqueous sodium chloride solution and extracted with ethyl
acetate. The organic extracts collected are dried over sodium
sulphate, and the solvent is removed. The residue is
chromatographed through silica gel (dichloromethane/methanol
19:1->2:1).
[0364] Yield: 0.060 g (49% of theory)
[0365] Mass spectrum (ESI.sup.+): m/z=390 [M+NH.sub.4].sup.+
[0366] The following compounds are obtained analogously to Example
14:
(15)
1-(.beta.-D-glucopyranos-1-yl)-3-(4-ethynyl-benzyl)-benzene
##STR00073##
[0368] Mass spectrum (ESI.sup.+): m/z=372 [M+NH.sub.4].sup.+
(16)
1-ethynyl-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethoxy-benzyl)-benzene
##STR00074##
[0370] Mass spectrum (ESI.sup.+): m/z=416 [M+NH.sub.4].sup.+
(17)
1-methoxy-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene
##STR00075##
[0372] Mass spectrum (ESI.sup.+): m/z=402 [M+NH.sub.4].sup.+
[0373] The compound according to Example (12)
(1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene)
may also be synthesised analogously to Example 14. Optionally, the
intermediate stage,
1-chloro-4-(2,3,4,6-tetra-O-acteyl-.beta.-D-glucopyranos-1-yl)-2-(4-ethyn-
yl-benzyl)-benzene, which is obtained after desilylation with
tetrabutylammonium fluoride, may be purified by recrystallisation
from ethanol.
##STR00076##
[0374] Mass spectrum (ESI.sup.+): m/z=406/408 (Cl)
[M+NH.sub.4].sup.+
[0375] The following compounds are also prepared analogously to the
above-mentioned Examples and other methods known from the
literature:
TABLE-US-00001 Ex. Structure (18) ##STR00077## (19) ##STR00078##
(20) ##STR00079## (21) ##STR00080## (22) ##STR00081## (23)
##STR00082## (24) ##STR00083## (25) ##STR00084## (26) ##STR00085##
(27) ##STR00086## (28) ##STR00087## (29) ##STR00088## (30)
##STR00089## (31) ##STR00090## (32) ##STR00091## (33) ##STR00092##
(34) ##STR00093## (35) ##STR00094## (36) ##STR00095## (37)
##STR00096## (38) ##STR00097## (39) ##STR00098## (40) ##STR00099##
(41) ##STR00100## (42) ##STR00101## (43) ##STR00102## (44)
##STR00103## (45) ##STR00104## (46) ##STR00105## (47) ##STR00106##
(48) ##STR00107## (49) ##STR00108## (50) ##STR00109## (51)
##STR00110## (52) ##STR00111## (53) ##STR00112## (54) ##STR00113##
(55) ##STR00114## (56) ##STR00115## (57) ##STR00116##
[0376] Some examples of formulations will now be described in which
the term "active substance" denotes one or more compounds according
to the invention, including the salts thereof. In the case of one
of the combinations with one or additional active substances as
described previously, the term "active substance" also includes the
additional active substances.
EXAMPLE A
Tablets Containing 100 mg of Active Substance
Composition:
TABLE-US-00002 [0377] 1 tablet contains: active substance 100.0 mg
lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg
magnesium stearate 2.0 mg 220.0 mg
Method of Preparation:
[0378] The active substance, lactose and starch are mixed together
and uniformly moistened with an aqueous solution of the
polyvinylpyrrolidone. After the moist composition has been screened
(2.0 mm mesh size) and dried in a rack-type drier at 50.degree. C.
it is screened again (1.5 mm mesh size) and the lubricant is added.
The finished mixture is compressed to form tablets. [0379] Weight
of tablet: 220 mg [0380] Diameter: 10 mm, biplanar, facetted on
both sides and notched on one side.
EXAMPLE B
Tablets Containing 150 mg of Active Substance
Composition:
TABLE-US-00003 [0381] 1 tablet contains: active substance 150.0 mg
powdered lactose 89.0 mg corn starch 40.0 mg colloidal silica 10.0
mg polyvinylpyrrolidone 10.0 mg magnesium stearate 1.0 mg 300.0
mg
Preparation:
[0382] The active substance mixed with lactose, corn starch and
silica is moistened with a 20% aqueous polyvinylpyrrolidone
solution and passed through a screen with a mesh size of 1.5 mm.
The granules, dried at 45.degree. C., are passed through the same
screen again and mixed with the specified amount of magnesium
stearate. Tablets are pressed from the mixture. [0383] Weight of
tablet: 300 mg [0384] die: 10 mm, flat
EXAMPLE C
Hard Gelatine Capsules Containing 150 mg of Active Substance
[0385] Composition:
TABLE-US-00004 1 capsule contains: active substance 150.0 mg corn
starch (dried) approx. 180.0 mg lactose (powdered) approx. 87.0 mg
magnesium stearate 3.0 mg approx. 420.0 mg
[0386] Preparation:
[0387] The active substance is mixed with the excipients, passed
through a screen with a mesh size of 0.75 mm and homogeneously
mixed using a suitable apparatus. The finished mixture is packed
into size 1 hard gelatine capsules.
[0388] Capsule filling: approx. 320 mg
[0389] Capsule shell: size 1 hard gelatine capsule.
EXAMPLE D
Suppositories Containing 150 mg of Active Substance
Composition:
TABLE-US-00005 [0390] 1 suppository contains: active substance
150.0 mg polyethyleneglycol 1500 550.0 mg polyethyleneglycol 6000
460.0 mg polyoxyethylene sorbitan monostearate 840.0 mg 2,000.0
mg
Preparation:
[0391] After the suppository mass has been melted the active
substance is homogeneously distributed therein and the melt is
poured into chilled moulds.
EXAMPLE E
Ampoules Containing 10 mg Active Substance
Composition:
TABLE-US-00006 [0392] active substance 10.0 mg 0.01 N hydrochloric
acid q.s. double-distilled water ad 2.0 ml
Preparation:
[0393] The active substance is dissolved in the necessary amount of
0.01 N HCl, made isotonic with common salt, filtered sterile and
transferred into 2 ml ampoules.
EXAMPLE F
Ampoules Containing 50 mg of Active Substance
[0394] Composition:
TABLE-US-00007 active substance 50.0 mg 0.01 N hydrochloric acid
q.s. double-distilled water ad 10.0 ml
Preparation:
[0395] The active substance is dissolved in the necessary amount of
0.01 N HCl, made isotonic with common salt, filtered sterile and
transferred into 10 ml ampoules.
* * * * *